Composite polypeptide with metal binding region and molecular construct thereof

By introducing metal binding domains to the polypeptide to form a complex with zinc ions, and using the sulfhydryl group of cysteine ​​residues for position-specific coupling, the problem of inefficient coupling of functional components in the prior art is solved, and the problem of inefficient coupling of functional components is achieved. Highly efficient and uniform coupling on the polypeptide.

CN113784989BActive Publication Date: 2024-11-15IMMUNWORK INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080024280.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-03-25
Filing Date
2020-03-25
Publication Date
2024-11-15
Estimated Expiration
2040-03-25

AI Technical Summary

Technical Problem

Existing biocoupling technologies lack chemical selectivity when coupling functional elements to polypeptide molecules, resulting in inefficiency and the production of heterogeneous products, especially the random lysine complex reactions in parent antibodies that lead to drugs- Antibody ratio (DAR) is uneven.

Method used

A composite polypeptide containing a metal binding domain is designed to form a complex with zinc ions and use the sulfhydryl group of cysteine ​​residues to perform position-specific chemical coupling to achieve efficient covalent coupling of functional elements. The amino acid sequence of the metal binding domain is CX1X2HA, where X1 is glycine or proline, X2 is glycine or alanine, located at the N- or C-terminus of the polypeptide, can form an amide bond with the SH-reactive group, and can perform position A dedicated coupling reaction.

Benefits of technology

The efficiency of position-specific coupling of functional elements on the polypeptide is improved, the production of heterogeneous products is reduced, and the uniformity of drug-antibody ratio and the chemical selectivity of biological couplings is enhanced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113784989B_ABST
    Figure CN113784989B_ABST
Patent Text Reader

Abstract

The present invention aims to disclose a composite polypeptide. According to various embodiments, the composite polypeptide comprises a parent polypeptide and a metal binding domain, which is capable of forming a complex with a metal ion. The composite polypeptide can be coupled to a binding unit with multiple functional elements to form a multifunctional molecular construct. Alternatively, multiple composite polypeptides can be coupled to a binding unit to form a molecular construct, or a polypeptide bundle. The present invention also discloses a binding unit suitable for coupling to the composite polypeptide with a metal binding domain.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a composite polypeptide with a metal binding domain, and in particular to a short oligopeptide capable of forming a complex with zinc ions. Background Art

[0002] Bioconjugation technology can be used to form a covalent bond between a biomolecule and another molecule (which may or may not be a biomolecule). Biomolecules generally refer to molecules that exist in organisms and are essential for biological processes. The biomolecules include natural and synthetic polypeptides or proteins, carbohydrates, lipids, nucleic acids and metabolites.

[0003] The concept of conjugating antibodies or antibody fragments to toxins (i.e., antibody-toxin conjugates (ATCs), cytotoxic drugs (i.e., antibody-drug conjugates (ADCs)), and radionuclides (i.e., antibody-radionuclide conjugates (ARCs)) emerged in the 1970s. The synthesis of such bioconjugates usually involves coupling reactions, such as coupling to surface-accessible lysine, cysteine, or tyrosine residues, and modification of surface-accessible lysine or tryptophan residues or N- and C-termini. However, there may be a large number of these amino acid residues in the parent antibody, and the coupling reaction usually occurs randomly. Therefore, such coupling reactions lack chemical selectivity and efficiency, and often result in heterogeneous products. For example, previous studies on huN901-DM1 (maytansinoid-monoclonal antibody immune complex) showed that the drug-to-antibody ratio (DAR) of ADC samples complexed with lysine ranged from 0 to 6 and could contain more than 4.5 million unique molecules.

[0004] In view of this, there is an urgent need in the art for a coupling technology that can efficiently couple a functional element to a specific position on a biological molecule (especially a polypeptide molecule). The present invention provides a solution to this need. Summary of the invention

[0005] The purpose of this summary is to provide a simplified summary of the present disclosure so that the reader has a basic understanding of the present disclosure. This summary is not a complete overview of the present disclosure, and it is not intended to point out important / key elements of the embodiments of the present invention or to define the scope of the present invention. Its only purpose is to present some of the concepts disclosed herein in a simplified form as a preface to the embodiments presented later.

[0006] One embodiment of the present invention relates to a metal binding domain that is capable of forming a complex with zinc ions under appropriate conditions.

[0007] According to one embodiment of the present disclosure, the metal binding domain comprises the following amino acid sequence: CX 1 X 2 HA (SEQ ID NO: 1), from N-terminus to C-terminus or from C-terminus to N-terminus, wherein X 1 is glycine or proline, X 2 is glycine or alanine, and the metal binding domain is located at the N- or C-terminus of the parent polypeptide. Exemplary embodiments of the metal binding domain include, but are not limited to: CGGHA (SEQ ID NO: 2), CPGHA (SEQ ID NO: 3), CGAHA (SEQ ID NO: 4), CPAHA (SEQ ID NO: 5), GCGGHA (SEQ ID NO: 6), ACPGHA (SEQ ID NO: 7) and GCPGHA (SEQ ID NO: 8).

[0008] In another embodiment, the present disclosure is about a composite polypeptide comprising a metal binding domain as described in the above embodiment / implementation. The composite polypeptide is thus able to form a complex with a metal ion through the metal binding domain under appropriate conditions. In this way, the sulfhydryl group in the cysteine ​​residue that forms a complex with the metal ion is more reactive than the sulfhydryl group in the cysteine ​​residue that does not form a complex with the metal ion. It is understood that the complex can be chemically coupled to another chemical formula or biological molecule in a position-specific manner to obtain a bioconjugate.

[0009] According to one embodiment of the present disclosure, the composite polypeptide comprises a parent polypeptide and a metal binding domain located at the N- or C-terminus of the parent polypeptide. In certain optional embodiments, there are 1 to 10 glycine residues as intermediate sequences between the parent polypeptide and the metal binding domain, while in other embodiments, the metal binding domain proposed herein is directly located before or after the parent polypeptide.

[0010] In yet another embodiment, one or more functional elements may be covalently coupled to the composite polypeptides proposed in the above embodiments / implementations of the present disclosure, and this reaction is carried out through the sulfhydryl (SH) group of the cysteine ​​residue in the metal binding domain of the composite polypeptide, thereby obtaining a molecular construct (or bioconjugate).

[0011] According to an embodiment adopted as required by the present disclosure, the SH-reactive group is a maleimide group, an iodoacetyl group, a bromoacetyl group, a vinylsulfone group, a monosulfone group, a methylsulfonylbenzothiazolyl group or a 2-pyridyldithiol group.

[0012] In certain optional embodiments, the composite polypeptide is in the form of a dimer; for example, the composite polypeptide may include an Fc region, F(ab')2, or a portion of an antibody. In these cases, each composite polypeptide chain may have a functional element coupled to it.

[0013] According to various embodiments of the present disclosure, the functional element is a small molecule entity that can induce a desired therapeutic effect. For example, the small molecule entity can be a cytotoxic drug, a toll-like receptor (TLR) agonist, or a chelator complexed with a radionuclide. Alternatively, the functional element is a fatty acid chain that can change the pharmacokinetic properties of the parent polypeptide or molecular construct as a whole.

[0014] Alternatively, the functional element may be in the form of a binding unit (also known as a "molecular bundle"). According to certain embodiments of the present disclosure, the binding unit comprises a central core and a plurality of target elements, effector elements or pharmacokinetic elements.

[0015] Specifically, the central core comprises 2 to 10 lysine (K) residues. Any two K residues are adjacent to each other or separated by a filler. In some examples, an SH-reactive group is connected to the first or last K residue of the central core by forming an amide bond therewith. In other examples, the central core further comprises a terminal spacer, and the SH-reactive group is connected to the terminal amino acid residue of the terminal spacer by forming an amide bond therewith. The terminal spacer can be an N-terminal spacer connected to the N-terminus of the first K residue, or a C-terminal spacer connected to the C-terminus of the last K residue. The filler and the terminal spacer independently comprise at least: (1) 1 to 12 non-K amino acid residues, or (2) a PEGylated amino acid having 2 to 12 ethylene glycol (EG) repeating units.

[0016] According to certain embodiments of the present disclosure, the central core carries a local negative charge at or near the amino acid residue linked to the SH-reactive group. For example, the local negative charge occurs at the first 5 to 15 amino acid residues from the amino acid residue linked to the SH-reactive group. Specifically, the local negative charge occurs in the first 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acid residues from the amino acid residue linked to the SH-reactive group. The local negative charge can be formed using one or more amino acid residues that carry a negative charge at pH = 7 (such as aspartic acid (D) and glutamic acid (E) residues). Alternatively, the central core can be coupled to a plurality of negatively charged effector elements.

[0017] In some examples, each target element, effector element or pharmacokinetic element is linked to the K residue of the central core by forming an amide bond with the ε-amino group of the K residue. In other examples, the molecular construct further comprises 2 to 10 connecting arms, wherein one end of each connecting arm is linked to the K residue of the central core by forming an amide bond with the ε-amino group of the K residue of the central core, and the other end of each connecting arm is linked to each target element, effector element or pharmacokinetic element. For example, the connecting arm can be a polypeptide comprising 2-12 non-K amino acid residues, or a PEGylated amino acid chain having 2 to 24 EG repeating units.

[0018] According to some embodiments of the present disclosure, the above-mentioned composite polypeptide can be used as a target element, which can guide the molecular construct to the target site or increase the relative amount of the molecular construct at the target site. In these cases, the joint unit (or molecular beam) can carry a plurality of effector elements, such as the small molecule entity described above.

[0019] According to some embodiments of the present disclosure, the composite polypeptide described above can be used as an effector element, which can cause the desired therapeutic effect in the individual. In these cases, the conjugated unit (or molecular beam) can carry a plurality of pharmacokinetic elements, such as C8-28 fatty acid derivatives or C8-28 dibasic fatty acid derivatives, to change or optimize the pharmacokinetic behavior of the molecular construct or composite polypeptide in the individual. According to various embodiments of the present disclosure, the ε-amino group of the K residue is connected to a C8-28 fatty acid derivative or a C8-28 dibasic fatty acid derivative. The above-mentioned fatty acid molecules can bind to serum albumin, and thus can improve the kinetic properties of the modified parent polypeptide in vivo.

[0020] The scope of the present disclosure also encompasses the above-described joining units, which are capable of forming a molecular construct with the composite polypeptides presented herein.

[0021] In yet another embodiment, the present disclosure relates to a junction unit that is capable of carrying a plurality of complex polypeptides as described in the above embodiments / implementations of the present disclosure. According to an embodiment of the present disclosure, the junction unit has a plurality of complex polypeptides covalently linked to a central core, and is therefore referred to as a polypeptide bundle.

[0022] According to certain embodiments of the present disclosure, the junction unit provided herein comprises a central core and a plurality of connecting arms.

[0023] Specifically, the central core comprises 2 to 10 lysine (K) residues. Any two K residues are adjacent to each other or separated by a filler. In some examples, a complexing group is connected to the first or last K residue of the central core by forming an amide bond therewith. Examples of complexing groups include, but are not limited to, azido, alkynyl, tetrazine, cyclooctenyl and cyclooctyne. In other examples, the central core further comprises a terminal spacer, and the SH-reactive group is connected to the terminal amino acid residue of the terminal spacer by forming an amide bond therewith. The terminal spacer can be an N-terminal spacer connected to the N-terminus of the first K residue, or a C-terminal spacer connected to the C-terminus of the last K residue. The filler and the terminal spacer independently comprise at least: (1) 1 to 12 non-K amino acid residues, or (2) a PEGylated amino acid having 2 to 12 EG repeating units.

[0024] According to some embodiments, one end of each linker is connected to the K residue of the central core by forming an amide bond with the ε-amino group of the K residue of the central core, and the other end of each linker is connected to each target element, effector element or pharmacokinetic element. For example, the linker can be a polypeptide comprising 2-12 non-K amino acid residues, or a PEGylated amino acid chain having 2 to 24 EG repeating units.

[0025] According to some embodiments of the present disclosure, the binding unit further comprises 2 to 10 composite polypeptides as described in the above embodiments / embodiments and a functional element. Each composite polypeptide is chemically coupled to the thiol group of the cysteine ​​residue in the metal binding domain via SH-reactive cross-linking.

[0026] According to certain optional embodiments of the present disclosure, each linker carries a local negative charge at or near the amino acid residue linked to the SH-reactive group. Specifically, the local negative charge appears at the first 5 to 15 amino acid residues from the amino acid residue linked to the SH-reactive group. For example, the local negative charge appears in the first 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acid residues from the amino acid residue linked to the SH-reactive group. The local negative charge can be formed by one or more amino acid residues that carry a negative charge at pH = 7, such as aspartic acid (D) and glutamic acid (E) residues.

[0027] After referring to the following embodiments, those skilled in the art to which the present invention belongs can easily understand the basic spirit and other invention purposes of the present invention, as well as the technical means and implementation schemes adopted by the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] In order to make the above and other objects, features, advantages and embodiments of the present invention more clearly understood, the accompanying drawings are described as follows.

[0029] Figure 1 The MALDI-TOF analysis result of the central core of Mal-peptide 1 according to one embodiment of the present invention;

[0030] Figure 2 The structure of the Mal-polypeptide 2-DOTA bundle according to one embodiment of the present invention;

[0031] Figure 3A This is the reverse phase analytical HPLC elution spectrum of Mal-peptide 2-DOTA bundle;

[0032] Figure 3B The MALDI-TOF analysis result of the Mal-peptide 2-DOTA beam according to one embodiment of the present invention;

[0033] Figure 4A The structure of the recombinant double-chain (scFvαCD19)-Fc-MBM-1 according to one embodiment of the present invention;

[0034] Figure 4B According to one embodiment of the present invention, the recombinant double-stranded L -V H Reducing SDS-PAGE analysis results of scFvαCD19)-Fc-MBM-1;

[0035] Figure 5 According to one embodiment of the present invention, the recombinant double-stranded L -V HNon-reducing SDS-PAGE analysis results of scFvαCD19)-Fc-MBM-2;

[0036] Figure 6 According to one embodiment of the present invention, the recombinant double-stranded L -V H Non-reducing SDS-PAGE analysis results of scFvαCD19)-Fc-MBM-3;

[0037] Fig. 7A The reduced SDS-PAGE analysis result of anti-CD19 antibody-MBM-1 or anti-CD19 antibody-MBM-2 according to one embodiment of the present invention;

[0038] Figure 7B The reduced SDS-PAGE analysis result of anti-CD19 antibody-MBM-1 or anti-CD19 antibody-MBM-2 according to one embodiment of the present invention;

[0039] Figure 8 The non-reducing SDS-PAGE analysis results of four (scFvαCD33)-Fc-MBM molecular constructs according to one embodiment of the present invention;

[0040] Fig. 9 According to an embodiment of the present invention, V L -V H and V H -V L Non-reducing SDS-PAGE analysis results of recombinant (scFvαCD20)-Fc-MBM-1 in two configurations;

[0041] Fig. 10A According to one embodiment of the present invention, the recombinant double-stranded H -V L Non-reducing SDS-PAGE analysis results of scFvαCD20)-Fc-MBM-2;

[0042] Fig. 10B According to one embodiment of the present invention, the recombinant double-stranded L -V H Non-reducing SDS-PAGE analysis results of scFvαCD20)-Fc-MBM-3;

[0043] Fig.11A According to one embodiment of the present invention, the recombinant double-stranded L -V H Non-reducing SDS-PAGE analysis results of scFvαCA19-9)-Fc-MBM-1;

[0044] Fig. 11BAccording to one embodiment of the present invention, the recombinant double-stranded L -V H Non-reducing SDS-PAGE analysis results of scFvαCA19-9)-Fc-MBM-2;

[0045] Fig. 12A According to one embodiment of the present invention, the recombinant double-stranded L -V H Non-reducing SDS-PAGE analysis results of scFvαCC38)-Fc-MBM-1;

[0046] Fig. 12B According to one embodiment of the present invention, the recombinant double-stranded L -V H Non-reducing SDS-PAGE analysis results of scFvαCC38)-Fc-MBM-2;

[0047] Fig.13A The structure of the recombinant double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle according to one embodiment of the present invention;

[0048] Fig. 13B The non-reducing SDS-PAGE analysis result of the recombinant double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle according to one embodiment of the present invention;

[0049] Fig.14 The non-reducing SDS-PAGE analysis result of the recombinant double-chain (scFvαCD19)-Fc-MBM-2 X 2 DOTA bundle according to one embodiment of the present invention;

[0050] Fig.15 The non-reducing SDS-PAGE analysis results of the recombinant double-chain (scFvαCD19)-Fc-MBM-3 X 2 DOTA bundle;

[0051] Fig.16 The reduced SDS-PAGE analysis result of the full-length anti-CD19 antibody-MBM-1 X 2 DOTA bundle according to one embodiment of the present invention;

[0052] Fig.17 The reduced SDS-PAGE analysis result of the full-length anti-CD19 antibody-MBM-2 X 2 DOTA bundle according to one embodiment of the present invention;

[0053] Fig.18 The non-reducing SDS-PAGE analysis result of the recombinant double-chain (scFvαCD33)-Fc-MBM-1 X 2 DOTA bundle according to one embodiment of the present invention;

[0054] Fig.19 The non-reducing SDS-PAGE analysis result of the recombinant double-chain (scFvαCD20)-Fc-MBM-1 X 2 DOTA bundle according to one embodiment of the present invention;

[0055] Fig. 20 The FPLC elution spectrum of the stable double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle through an anion exchange column according to one embodiment of the present invention;

[0056] Fig.21 The results of SDS-PAGE analysis of the fractions collected after the stable double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle was treated with an anion exchange column according to one embodiment of the present invention;

[0057] Fig. 22 The results of SDS-PAGE analysis of the fractions collected after the stable double-chain (scFvαCD20)-Fc-MBM-1 X 2 DOTA bundle was treated with an anion exchange column according to one embodiment of the present invention;

[0058] Fig.23 The MALDI-TOF analysis result of the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle according to one embodiment of the present invention;

[0059] Fig.24 According to one embodiment of the present invention, a stable double-chain (scFvαCD19)-Fc-MBM-1 X 2 chelate 89 Y 3+ MALDI-TOF analysis results of the DOTA beam of ions;

[0060] Fig.25 According to one embodiment of the present invention, a stable double-chain (scFvαCD19)-Fc-MBM-1 X 2 chelate 175 Lu 3+ MALDI-TOF analysis results of the DOTA beam of ions;

[0061] Fig.26 According to one embodiment of the present invention, a stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 111 TLC analysis results of the radiochemical purity of In-labeled DOTA bundles;

[0062] Fig. 27 According to one embodiment of the present invention, a stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2111 The results of stability analysis of In-labeled DOTA bundles by western blotting;

[0063] FIG. 28A to FIG. 28D The staining analysis results of the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2DOTA bundle according to one embodiment of the present invention;

[0064] Fig.29 The stability analysis result of the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle by SDS-PAGE according to one embodiment of the present invention;

[0065] Fig.30 The stability analysis result of the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle by TLC analysis according to one embodiment of the present invention;

[0066] Fig.31 is the half-life of the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle according to one embodiment of the present invention;

[0067] Fig.32 According to one embodiment of the present invention, the target effect of the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle on CD1-expressing xenograft tumors;

[0068] Fig.33 The biodistribution analysis results of the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle in CD1-expressing xenograft tumors according to one embodiment of the present invention;

[0069] Fig.34 is a schematic structural formula of Aib-GLP-1 agonist-Cys according to one embodiment of the present invention;

[0070] Fig.35 is a schematic structural formula of a Cys-somatin polypeptide according to one embodiment of the present invention;

[0071] Fig.36 The MALDI-TOF / TOF analysis result of Cys-somatin polypeptide according to one embodiment of the present invention;

[0072] Fig.37 is a schematic structural formula of a Cys-PSMA ligand according to one embodiment of the present invention;

[0073] Fig.38The ESI-MS analysis result of Cys-PSMA ligand according to one embodiment of the present invention;

[0074] Fig.39 is a schematic structural formula of calcitonin-MBM-1 according to one embodiment of the present invention;

[0075] Fig.40 is a schematic structural formula of a Mal-peptide 3-lenalidomide bundle according to one embodiment of the present invention;

[0076] Fig.41 The ESI-MS analysis result of the Mal-peptide 3-lenalidomide beam according to one embodiment of the present invention;

[0077] Fig.42 is a schematic structural formula of a Mal-peptide 4-lenalidomide bundle according to one embodiment of the present invention;

[0078] Fig.43 is a schematic structural formula of a Mal-polypeptide 5-fatty acid bundle according to one embodiment of the present invention;

[0079] Fig.44 The ESI-MS analysis result of the 5-fatty acid bundle of the Mal-peptide according to one embodiment of the present invention;

[0080] Fig.45 is a schematic structural formula of a 3-DOTA arm joint unit according to an embodiment of the present invention;

[0081] Fig.46 is an ESI-MS analysis result of a 3-DOTA arm bonding unit according to an embodiment of the present invention;

[0082] Fig.47 The SDS-PAGE analysis result of MBM-1-IL-2 according to one embodiment of the present invention;

[0083] Fig.48 The SDS-PAGE analysis result of double-chain (scFvαCD38)-Fc-MBM-1×2 lenalidomide bundle according to one embodiment of the present invention;

[0084] Fig.49 is a schematic structural formula of a somatostatin polypeptide X fatty acid bundle according to one embodiment of the present invention;

[0085] Fig.50A is a schematic structural formula of the fatty acid bundle of Aib-GLP-1 agonist X according to one embodiment of the present invention;

[0086] Fig.50B According to one embodiment of the present invention, teriparatide-MBM-1 X fatty acid bundle;

[0087] Fig.51A is a schematic structural formula of leuprorelin-MBM-3 X fatty acid bundle according to one embodiment of the present invention;

[0088] Fig.51B The MALDI-TOF analysis result of the fatty acid bundle of leuprorelin-MBM-3 X according to one embodiment of the present invention;

[0089] Fig.52A is a schematic structural formula of a 3-DOTA arm-joining unit X 3 PSMA ligand according to one embodiment of the present invention;

[0090] Fig.52B is the ESI-MS analysis result of the 3-DOTA arm-bonded unit X 3 PSMA ligand according to one embodiment of the present invention;

[0091] Fig.53 The SDS-PAGE analysis result of the purified double-chain (scFvαCA19-9)-Fc-MBM-1 X 2 DOTA bundle according to one embodiment of the present invention;

[0092] Fig.54 The SDS-PAGE analysis result of the purified double-chain (scFvαCD38)-Fc-MBM-1×2 lenalidomide bundle according to one embodiment of the present invention;

[0093] Fig.55 The MALDI-TOF analysis results of the purified double-chain (scFvαCD38)-Fc-MBM-1×2 lenalidomide beam according to one embodiment of the present invention;

[0094] Fig.56A and Fig.56B The half-life of the parent anti-CD38 hIgG1.Fc antibody and the double-chain (scFvαCD38)-Fc-MBM-1×2 lenalidomide bundle according to one embodiment of the present invention;

[0095] FIG. 57A to FIG. 57C According to one embodiment of the present invention, the target effect of the double-chain (scFvαCD38)-Fc-MBM-1×2 lenalidomide bundle; and

[0096] Fig.58A and Fig.58B FIG. 1 is the ADCC effect of the double-chain (scFvαCD38)-Fc-MBM-1×2 lenalidomide bundle according to an embodiment of the present invention. DETAILED DESCRIPTION

[0097] In order to make the description of the present disclosure more detailed and complete, the following is an illustrative description of the implementation scheme and specific implementation of the present invention; however, this is not the only form of implementing or using the specific implementation of the present invention. The implementation covers the features of multiple specific implementations and the method steps and sequences used to construct and operate these specific implementations. However, other specific implementations can also be used to achieve the same or equivalent functions and step sequences.

[0098] For the convenience of explanation, some words used in the specification, examples and attached patent claims are sorted here. Unless otherwise defined in this specification, the meanings of scientific and technical words used herein are the same as those understood and used by technicians in the technical field to which the present invention belongs.

[0099] In the absence of conflict with the context, the singular nouns used in this specification include the plural form of the noun; and the plural nouns used also include the singular form of the noun. In addition, in this specification and the scope of the patent application, the expressions "at least one" and "one or more" have the same meaning, both of which represent the inclusion of one, two, three or more. Similarly, the term "at least two" represents the inclusion of two, three, four or more. What is more, in this specification and the scope of the patent application, "at least one of A, B and C", "at least one of A, B or C" and "at least one of A, B and / or C" mean that only A, only B, only C, both A and B, both B and C, both C, and A, B and C are included.

[0100] Although the numerical ranges and parameters used to define the broader scope of the present invention are approximate values, the relevant numerical values ​​in the specific embodiments have been presented as accurately as possible. However, any numerical value inherently inevitably contains standard deviations due to individual testing methods. Here, "about" generally means that the actual value is within plus or minus 10%, 5%, 1% or 0.5% of a specific value or range. Alternatively, the term "about" means that the actual value falls within the acceptable standard error of the mean value, depending on the consideration of a technician in the technical field to which the present invention belongs. Except for the examples, or unless otherwise explicitly stated, it should be understood that all ranges, quantities, values ​​and percentages used herein (for example, to describe the amount of material, the length of time, temperature, operating conditions, quantitative ratios and the like) are modified by "about". Therefore, unless otherwise stated to the contrary, the numerical parameters disclosed in this specification and the attached patent scope are all approximate values ​​and can be changed as needed. At least these numerical parameters should be understood as the number of significant digits indicated and the values ​​obtained by applying the general rounding method. Herein, numerical ranges are expressed from one end point to another point or between two end points; unless otherwise stated, the numerical ranges described herein include the end points.

[0101] Here, the term "targeting element" refers to a portion of a molecular construct that can directly or indirectly bind to a target (e.g., a receptor on the surface of a cell or a protein in a tissue), thereby assisting in delivering the molecular construct of the present invention to the target. In some cases, the targeting element can guide the molecular construct to a nearby target cell. In other cases, the targeting element can specifically bind to a molecule on the surface of a target cell; or the targeting element can specifically bind to a second molecule, and this second molecule can specifically bind to a molecule on the surface of a target cell. In some cases, once the targeting element is bound to the target object, the targeting element can internalize the molecular construct of the present invention and move it into the cytoplasm of the target cell. The targeting element can be an antibody or ligand for a cell surface receptor; or a molecule that can bind to the above-mentioned antibody or ligand, thereby indirectly targeting the molecular construct of the present invention to the target site (e.g., the surface of a selected cell). Compared with therapeutic drugs without targeting functions, the use of the molecular construct of the present invention can enhance or facilitate the localization of the effector element (therapeutic agent) at the disease site. The above-mentioned localization is a degree or relative ratio, rather than an absolute or complete localization of the response element to the disease site.

[0102] According to the present invention, the term "effector element" refers to a portion of a molecular construct that is capable of exerting biological activity (e.g., inducing or suppressing immune activity, exerting cytotoxicity, inhibiting enzyme activity and the like) or other functional activity (e.g., recruiting immune cells or other therapeutic molecules) once the molecular construct reaches the target site. "Effect" may refer to a therapeutic or diagnostic effect. Effector elements include elements that can bind to cells and / or extracellular immunomodulatory factors. The above-mentioned effector elements include substances such as proteins, nucleic acids, lipids, carbohydrates, glycoproteins, drug moieties (including small molecule drugs and biological preparations), compound elements and isotopes, and also include fragments of the above-mentioned substances.

[0103] According to the present invention, the "pharmacokinetic element" refers to an element that can change at least one of the following characteristics of a molecular construct: solubility, clearance rate, half-life and bioavailability. For example, the pharmacokinetic element can be a long PEG chain with a molecular weight between about 20,000 and 50,000 Daltons. Alternatively, the pharmacokinetic element can include a C8-28 fatty acid chain or a C8-28 dibasic fatty acid chain.

[0104] The "bioconjugate" described in the present disclosure refers to a molecular construct comprising the composite polypeptide disclosed herein and one or more functional elements.

[0105] Although the terms "first", "second", "third", etc. are used herein to describe various elements, components, regions and / or sections, these elements (and components, regions and / or sections) are not limited by the above modifiers. In addition, unless the context clearly indicates otherwise, the use of these ordinals does not imply a sequence or order. Instead, these terms are only used to distinguish between the elements. Therefore, the first element described below can also be named the second element without departing from the disclosure of the exemplary embodiments.

[0106] Herein, the terms “link,” “couple,” and “conjugate” are used interchangeably and are all used to refer to connecting two elements together through a direct or indirect connection relationship.

[0107] The term "polypeptide" as used herein refers to a polymer having at least two amino acid residues. In general, a polypeptide comprises 2 to 200 amino acid residues; preferably, 2 to 50 residues. The amino acid sequence mentioned in this specification encompasses L-, D- or β-amino acid forms of such sequences. Polypeptides also include amino acid polymers in which one or more amino acid residues are artificial chemical analogs corresponding to a natural amino acid, and of course naturally occurring amino acid polymers. In addition, this term also encompasses amino acids connected in polypeptide chains or other ways, such as modified linkages, such as replacing polypeptide bonds with α-esters, β-esters, thioamides, phosphoramides, carbomates, hydroxylate bonds, and the like.

[0108] In some embodiments, the scope of the present invention also encompasses other proteins with conservative substitutions compared to the sequence. In various embodiments, one, two, three, four or five different residues are substituted. As used herein, the term "conservative substitution" means that the amino acid substitution does not significantly change the activity of the molecule (e.g., biological or functional activity and / or specificity). Generally speaking, conservative amino acid substitutions are substitutions of an amino acid with another amino acid having similar chemical properties (e.g., charge or hydrophobicity). Certain conservative substitutions include "analog substitutions," which are substitutions of standard amino acids with non-standard (e.g., rare or synthetic) amino acids, where the difference between the non-standard amino acid and the original amino acid being substituted is minimal. The amino acid analogs, such as isomers or metabolic precursors, can be obtained by artificially modifying standard amino acids without significantly changing the original amino acid structure. In the present disclosure, the following amino acid residues are considered to belong to four distinct amino acid classes: (1) lysine, which has an amino group on its side chain; (2) cysteine, which has a thiol group on its side chain; (3) serine and threonine, which have a hydroxyl group on its side chain; and (4) aspartic acid and glutamic acid, which have a carboxyl group on their side chains. Each of these four classes of amino acids has a unique functional group on its side chain that can be used to complex with different chemical components. Unnatural amino acids with such functional groups can also be used to achieve similar purposes. It should be noted that the carboxyl group of aspartic acid or glutamic acid can react with the amino group of an element to form an amide bond. This reaction chemistry is similar to the amide bond formation reaction between the amino group of a lysine residue and an element with a carboxyl group. Therefore, an aspartic acid or glutamic acid residue can be used to replace a lysine residue in the central core, and the first element can also be connected to the central core through the same reaction chemistry to form an amide bond.

[0109] In some embodiments, the scope of the present invention also covers any sequence having at least 80% sequence similarity to any of the aforementioned sequences, preferably at least 85% or 90%, more preferably at least 95% or 98%.

[0110] The "percentage (%) aminoacid sequence identity" for the polypeptide sequence herein refers to the percentage of amino acid residues in the candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence; when performing the above comparison, the candidate polypeptide fragment and the specific polypeptide fragment may be placed side by side, and a gap may be introduced when necessary so that the two sequences form the highest sequence similarity; when calculating the similarity, conservatively substituted amino acid residues are regarded as different residues. There are a variety of methods available in the related art for performing the above alignment, such as publicly available software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR), etc. When performing the alignment, a person skilled in the art to which the present invention belongs may select appropriate parameters and calculation methods to obtain the best arrangement. In this specification, the sequence comparison between two polypeptide sequences is performed using Blastp, a protein-protein BLAST analysis database provided by the National Center for Biotechnology Information (NCBI) of the United States. The calculation method of the amino acid sequence similarity between the candidate polypeptide sequence A and the reference polypeptide sequence B (also referred to in this specification as the amino acid sequence similarity between the polypeptide sequence A and the polypeptide sequence B having a specific percentage (%)) is as follows:

[0111]

[0112] Where X is the number of identical amino acid residues obtained by aligning sequences A and B using the BLAST sequence alignment program, and Y is the total number of amino acid residues in the shorter sequence A or B.

[0113] The term "PEGylated amino acid" herein refers to a polyethylene glycol (PEG) chain with an amino group and a carboxyl group. Generally, the structural formula of a PEGylated amino acid is NH 2 -(CH 2 CH 2 O) n In the present disclosure, the value of n is between 1 and 20; preferably between 2 and 12.

[0114] The term "conjugating moiety" refers to a molecule with one or more functional groups that are chemically reactive and capable of covalently bonding to other chemical units. Non-limiting examples of such functional groups include carboxyl, carbonyl, hydroxyl, thiol, amino, tert-Butyldimethylsilyl (TBDMS), N-hydroxysuccinimidyl (NHS), SH-reactive groups (e.g., maleimide, haloacetyl, sulfone, or pyridyldisulfide), iodine (iodo), iodoacetamide, azide, alkynyl, cyclooctynyl, tetrazine, cyclooctenyl, and cyclooctynyl. According to an embodiment of the present disclosure, the composite portion of the bonding unit proposed herein has two functional groups, one of which is a carboxyl group or an amino group, and this functional group is used to form an amide bond with the α-amino group or the carboxyl group of the spacer, so that the composite portion is bonded to the N-terminus or the C-terminus of the spacer; and the other is an SH-reactive group, which is used to bond with the second element through SH-reactive cross-linking chemistry.

[0115] Here, the "end" of a polypeptide refers to the amino acid residue at the N-terminus or C-terminus of the polypeptide. When describing the constituent units of a polymer (such as polyethylene glycol described herein), the "end" refers to the part at the end of the polymer backbone. In this specification and patent scope, the term "free end" is used to refer to the terminal amino acid residue or constituent unit that is not chemically bonded to another molecule.

[0116] The term "antigen" or "Ag" refers to a molecule that can cause an immune response. Such an immune response may involve a secretory, hormonal, and / or cellular antigen-specific response. In the present disclosure, the term "antigen" refers to a protein, a polypeptide (including mutants or biologically active fragments thereof), a polysaccharide, a glycoprotein, a lipopolysaccharide, a nucleic acid, or a combination thereof.

[0117] In this specification and the scope of the patent application, the term "antibody" should be interpreted in a broad sense and includes fully assembled antibodies, antibody fragments that can bind to antigens, such as antigen-binding fragments (Fab / Fab'), F(ab')2 fragments (having two Fab parts connected to each other by disulfide bonds), variable fragments (variable fragments, Fv), single-chain variable fragments (scFv), bi-single-chain variable fragments (bi-scFv), nanobodies (also known as single-domain antibodies (sdAb)), unibodies and diabodies. "Antibody fragments" include a portion of a complete antibody, preferably including the antigen-binding region or variable region of the complete antibody. Antibody fragments may include a pair of scFvs, which are linked to the N- or C-terminus of a pair of CH2-CH3 segments derived from human γ4 or γ1 immunoglobulin. In a typical example, "antibody" refers to a protein substantially composed of one or more polypeptides encoded by immunoglobulin genes or fragments thereof. Conventional immunoglobulin genes include constant region genes such as κ (kappa), λ (lambda), α (α), γ (gamma), δ (gamma), ε (epsilon) and μ (mu), as well as numerous immunoglobulin variable region genes. Light chains are usually classified as κ (kappa) or λ (lambda). Heavy chains are usually classified as γ (gamma), μ (mu), α (α), δ (gamma) or ε (epsilon). Based on these structures, the following types of immunoglobulins are defined: IgG, IgM, IgA, IgD and IgE. The typical immunoglobulin antibody structure is a tetramer. Each tetramer is composed of two identical polypeptide chains, and each pair has a "light" chain (about 25kDa) and a "heavy" chain (about 50-70kDa). The N-terminus of each chain defines a variable region consisting of about 100 to 110 or more amino acids that is primarily responsible for antigen recognition. L ) and variable heavy chain (V H) refer to the above-mentioned light chain and heavy chain respectively. According to the embodiments of the present disclosure, the above-mentioned antibody fragments can be resynthesized by changing natural antibodies or using recombinant DNA. In some embodiments of the present disclosure, the above-mentioned antibodies and / or antibody fragments can have bispecificity and can have a variety of different configurations. For example, bispecific antibodies can include two different antigen binding sites (variable regions). In various embodiments, bispecific antibodies can be prepared using fusion tumor technology or recombinant DNA technology. In some embodiments, bispecific antibodies have binding specificity for at least two different epitopes. In many molecular configurations using antibody fragments, antibody mimetics can be used to replace fragments, and such mimetics can bind to the same antigenic components as antibody fragments. Mimetics include anticalins, pre-designed ankyrin repeat proteins (DARPins), affibodies, fynomers, ankyrins, avimers and other analogs.

[0118] The term "specifically bind" as used herein refers to the ability of an antibody or antigen-binding fragment thereof to bind to an antigen with a dissociation constant (Kd) of less than about 1×10 -6 M, 1×10 -7 M, 1×10 -8 M, 1×10 -9 M, 1×10 -10 M, 1×10 -11 M or 1×10 -12 M; Alternatively or additionally, the antibody or antigen-binding fragment thereof binds to the antigen with an affinity that is more than twice as strong as its binding affinity to a non-specific antigen.

[0119] The term "treatment" refers to preventive (e.g., prophylactic medication), curative, or palliative treatment to achieve a desired pharmaceutical and / or physiological effect; and the act of treating includes the above-mentioned preventive, curative, or palliative treatment. Specifically, treatment refers to the administration or administration of a molecular construct of the present invention or a pharmaceutical composition comprising the molecular construct to an individual who may suffer from a medical condition, symptom, disease, or abnormality associated with a disease, or who is susceptible to a disease, in order to partially or completely alleviate, improve, alleviate one or more symptoms or characteristics of a specific abnormality and / or condition, or to delay its occurrence, hinder its progression, reduce its severity, and / or reduce its incidence. Treatment can also be performed on individuals who have not yet shown signs of a disease, abnormality, and / or condition and / or individuals who have shown early signs, in order to reduce the risk of developing pathological changes associated with the disease, abnormality, and / or condition.

[0120] As used herein, the term "effective amount" refers to an amount of the molecular construct of the present invention sufficient to induce the desired therapeutic response. An effective amount of an agent is not necessarily capable of curing a disease or condition, but is capable of delaying, hindering or preventing the occurrence of the disease or condition, or is capable of alleviating symptoms associated with the disease or condition. A therapeutically effective amount may be divided into one, two or more doses and administered once, twice or more times in an appropriate dosage form within a specified period. The specific therapeutically effective amount depends on a variety of factors, such as the specific condition to be treated, the physiological condition of the individual (e.g., individual weight, age or sex), the type of individual being treated, the duration of treatment, the nature of concurrent treatment (if any), and the specific formulation used and the structure of the compound or its derivative. For example, a therapeutically effective amount may be expressed as the total weight of the active ingredient, such as in grams, milligrams or micrograms; or as a ratio of the weight of the active ingredient to body weight, such as in milligrams per kilogram of body weight (mg / kg).

[0121] The terms "application" and "administration" are used interchangeably herein and refer to providing the molecular construct or pharmaceutical composition of the present invention to a subject in need of treatment.

[0122] The terms "subject" or "patient" are used interchangeably herein and refer to animals (including humans) that can be treated with the molecular constructs, pharmaceutical compositions and / or methods of the present disclosure. Unless otherwise specified, "subject" or "patient" generally includes males and females. "Subject" or "patient" includes any mammal that can benefit from the treatment of the present disclosure. Examples of the "subject" or "patient" include, but are not limited to: humans, rats, mice, guinea pigs, monkeys, pigs, goats, cattle, horses, dogs, cats, birds and poultry. In one example, the patient is a human. The mammal covers all members of the class Mammalia, including humans, primates, domestic and farm animals (such as rabbits, pigs, sheep and cattle), zoo animals or competition animals, pets, and rodents (such as mice and rats). The term "non-human mammals" covers all members of the class Mammalia except humans.

[0123] According to several embodiments of the present disclosure, the term "metal binding domain" refers to a segment of an oligopeptide that is capable of binding to metal ions, such as Zn 2+ 、Ni 2+ 、Co 2+ , Fe 2+ , Mn 2+ Cu 2+ In certain embodiments, a metal binding domain capable of binding to a zinc ion is also referred to as a "zinc binding domain"; however, a person skilled in the art to which the present invention relates should understand that such a binding domain may also bind to other metal ions that have similar physical and / or chemical properties to zinc ions.

[0124] The present disclosure is based at least on a variety of novel metal binding domains that can be attached to the N- or C-terminus of a parent polypeptide. The metal binding domains proposed herein have the following advantages in constructing bioconjugates. First, the metal binding domains proposed herein are derived from human sequences, and therefore have lower immunogenicity than other metal binding domains that do not belong to the human genome. Second, the composite polypeptides with the metal binding domains proposed herein have ideal expression levels, and the expressed composite polypeptides are quite stable during storage, coupling and purification. Third, the metal binding domains proposed herein can easily perform site-specific coupling reactions between the SH groups of the cysteine ​​residues of the metal binding domain and the SH-reactive groups of the functional elements when the cysteine ​​residues of the parent polypeptide are mostly unreactive. Therefore, the present disclosure proposes a method for constructing multifunctional bioconjugates. Various embodiments and implementations of the present disclosure are disclosed below.

[0125] (I) Metal binding domain

[0126] The first embodiment of the present disclosure is directed to a metal binding domain that can form a complex with a metal ion under appropriate conditions. The metal ion, such as Zn 2+ 、Ni 2+ 、Co 2+ , Fe 2+ , Mn 2+ Cu 2+ .

[0127] According to one embodiment of the present disclosure, the metal binding domain comprises the following amino acid sequence: CX 1 X 2 HA (SEQ ID NO: 1), from N-terminus to C-terminus or from C-terminus to N-terminus, wherein X 1 is glycine or proline, X 2 is glycine or alanine. Exemplary metal binding domains include, but are not limited to, CGGHA (SEQ ID NO: 2), CPGHA (SEQ ID NO: 3), CGAHA (SEQ ID NO: 4), CPAHA (SEQ ID NO: 5), GCGGHA (SEQ ID NO: 6), ACPGHA (SEQ ID NO: 7), and GCPGHA (SEQ ID NO: 8).

[0128] (II) Composite polypeptides with metal binding domains

[0129] Another embodiment of the present disclosure is a composite polypeptide comprising a metal binding domain as described in the above embodiments / implementations. Therefore, the composite polypeptide can form a complex with metal ions through the metal binding domain under appropriate conditions.

[0130] According to one embodiment of the present disclosure, the composite polypeptide comprises a parent polypeptide and a metal binding domain according to the above embodiment / embodiment of the present disclosure. In various embodiments, the metal binding domain is attached to the N- or C-terminus of the parent polypeptide, or is connected through one or more intermediate amino acid residues. In an optional embodiment, the intermediate sequence can be 2 to 10 glycine residues.

[0131] According to various embodiments of the present disclosure, when the metal binding domain is located at the N-terminus of the parent polypeptide, the sequence of the metal binding domain can be CX 1 X 2 HA (SEQ ID NO: 1), from N-terminus to C-terminus or from C-terminus to N-terminus, wherein X 1 is glycine or proline and X 2 Similarly, when the metal binding domain is located at the C-terminus of the parent polypeptide, the sequence of the metal binding domain may be CX1 X 2 HA (SEQ ID NO: 1), from N-terminus to C-terminus or from C-terminus to N-terminus, wherein X 1 is glycine or proline and X 2 It is glycine or alanine.

[0132] According to various embodiments of the present disclosure, the parent polypeptide may be a peptide hormone or its equivalent. The equivalent of the peptide hormone includes functional fragments, precursors, analogs or derivatives known to those skilled in the art. Illustrative examples of peptide hormones described herein include adrenocorticotropic hormone (ACTH), amylin, angiotensin, atrial natriuretic peptide (ANP), C-type natriuretic peptide (CNP), calcitonin, cholecystokinin (CCK), gastrin, ghrelin, glucagon, growth hormone, follicle-stimulating hormone (FSH), insulin, leptin, melanocyte-stimulating hormone (MSH), oxytocin, parathyroid hormone (PTH), prolactin, renin, somatostatin, thyroid-stimulating hormone (TSH), hormone, TSH), thyrotropin-releasing hormone (TRH), vasopressin, and vasoactive intestinal peptide. For example, equivalents of insulin include, but are not limited to, lispro, aspart, glulisine, detemir, degludec, and glargine. Equivalents of calcitonin include, but are not limited to, calcitonin and adrenomedullin. Equivalents of somatostatin include, but are not limited to, octreotide and lanreotide.

[0133] In certain embodiments, the parent polypeptide may be a peptidomimetic ligand that can bind to certain cell surface receptors. Peptidomimetics are short protein-like chains that are designed to mimic the function of polypeptides. For example, a series of peptidomimetic molecules based on glutamate-urea-lysine and having PSMA binding ability have been designed.

[0134] In an optional embodiment, the parent polypeptide can be an antibody, such as a monoclonal antibody, immunoglobulin A (IgA), IgD, IgE, IgG or IgM. The scope of the present disclosure also covers functional fragments or derivatives of intact antibodies, examples of which include but are not limited to: bispecific antibodies, chimeric antibodies, human antibodies, humanized antibodies, single-chain antibodies (scAb), single-chain variable fragments (scFv), tandem two-scFvs, tandem three-scFvs, diabodies, triabodies, tetrabodies, Fab fragments, F(ab')2 fragments, Fds, domain antibodies, and minibodies.

[0135] Alternatively, the parent polypeptide may be a cytokine or its equivalent. Equivalents of cytokines include functional fragments, precursors, analogs or derivatives known to those skilled in the art of the present invention. Exemplary cytokines described herein include, but are not limited to, interleukin-2 (IL-2), IL-10, IL-12, interferon-α (IFN-α), IFN-γ, transforming growth factor-β (TGF-β) and tumor necrosis factor-α (TNF-α).

[0136] In certain embodiments, the parent polypeptide may be a single-chain antibody fragment, such as a single domain antibody (sdAb), a single chain antibody (scAb), a single chain variable fragment (scFv), a bi-specific T-cell engager (BiTE), a tandem di-scFv, and a tandem tri-scFv. In other embodiments, the parent polypeptide may be an antibody fragment derived from a heavy chain or a light chain of an immunoglobulin, and the composite polypeptides provided herein include a portion of a complete antibody, a crystallizable region fragment (fragment crystallizable region, Fc region), an antigen binding fragment (fragment antigen binding fragment, Fab), Fab', F(ab')2, Fab', Fv, (scFv)2, sc(Fv)2, a diabody, Fd, Fd', or a minibody. The immunoglobulin may be derived from immunoglobulin D (IgD), IgE, or IgG. The antibody may be a bi-specific antibody, a chimeric antibody, a human antibody, or a humanized antibody.

[0137] In certain embodiments, the antibody (or functional fragment thereof) is specific for a cell surface antigen that is associated with or overexpressed on liquid tumors. Exemplary examples of such cell surface antigens include: CD5, CD19, CD20, CD22, CD23, CD27, CD30, CD33, CD34, CD37, CD38, CD43, CD72a, CD78, CD79a, CD79b, CD86, CD134, CD137, CD138, and CD319. Antibodies to these cell surface antigens (or fragments or derivatives thereof) can be used as targeting elements to bring molecular constructs with targeting elements to the disease site. In other embodiments adopted as needed, the antibodies (and functional fragments or derivatives thereof) may be specific for other cell surface antigens, and such antibodies may exert therapeutic effects in the human body; examples of such cell surface antigens include: CD3, CD16a, CD28, CD134, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1).Alternatively, the antibody (or fragment thereof) may be specific for a tumor-associated antigen (TAA), such as human epidermal growth factor receptor-1 (HER1), HER2, HER3, HER4, carbohydrate antigen 19-9 (CA 19-9), carbohydrate antigen 125 (CA 125), carcinoembryonic antigen (CEA), mucin 1 (MUC 1), ganglioside GD2, melanoma-associated antigen (MAGE), prostate-specific membrane antigen (PSMA), prostate stem cell antigen (PSCA), mesothelin, mucin-associated Tn antigen, sialyl Tn antigen, Globo H, stage-specific embryonic antigen (MEA), prostate-specific membrane antigen (PSMA), prostate stem cell antigen (PSCA), mesothelin, mucin-associated Tn antigen, sialyl Tn antigen, Globo H, stage-specific embryonic antigen (MEA), prostate-specific membrane antigen (PSMA), prostate stem cell antigen (PSCA), prostate-specific Tn antigen, ... Each TAA is usually overexpressed on the cell surface of one or more solid tumors. Antibodies to such TAAs can be used as a targeting element and used to prepare the molecular constructs described herein. In other optional embodiments, the antibody (or its fragment) is specific for a growth factor, and the growth factor is selected from the group consisting of the following substances: epidermal growth factor (EGF), mutant EGF, epiregulin, heparin-binding epidermal growth factor (HB-EGF), vascular endothelial growth factor A (VEGF-A), basic fibroblast growth factor (bFGF) and hepatocyte growth factor (HGF). In certain embodiments, the antibody (or its fragment) is specific for the cytokines mentioned above.

[0138] (III) Molecular constructs formed by functional elements and composite polypeptides with metal binding domains

[0139] In yet another embodiment, one or more functional elements can be covalently coupled to the composite polypeptide according to the above embodiments / implementations of the present disclosure by reacting with the sulfhydryl (SH) group of the cysteine ​​residue in the metal binding domain of the composite polypeptide to form the molecular construct (or bioconjugate) of the present invention. Specifically, the metal binding activity of the composite polypeptide enables a position-specific complexing reaction, thereby obtaining a homogeneous molecular construct.

[0140] According to an embodiment adopted as required by the present disclosure, the SH-reactive group is a maleimide group, an iodoacetyl group, a bromoacetyl group, a vinylsulfone group, a monosulfone group, a methylsulfonylbenzothiazolyl group or a 2-pyridyldithiol group.

[0141] It can be understood that the functional element can be an effector element that can produce the desired therapeutic effect in the individual. Alternatively, the functional element can be a target element that can guide the molecular construct to the target site in the individual. Alternatively, the functional element can be a pharmacokinetic element that can change the pharmacokinetic expression of the molecular construct in the individual. Alternatively, the functional element is presented in the form of a junction unit (or molecular beam). According to certain embodiments of the present disclosure, the junction unit comprises a central core and a plurality of target elements, effector elements or pharmacokinetic elements; the structure of the junction unit is described in Section (IV) below.

[0142] Effector molecules useful in the present disclosure include, but are not limited to, cytotoxic drugs, TLR agonists, or chelators (alone or complexed with radionuclides).

[0143] It is understood that the cytotoxic drugs that can exert cytotoxic effects on tumor cells can be: anti-estrogen (such as tamoxifen, raloxifene and megestrol), LHRH agonist (such as goscrclin and leuprolide), anti-androgen (such as flutamide and bicalutamide), photodynamic therapy agents (such as vertoporfin, phthalocyanine, photosensitizer Pc4 and demethoxy-hypocrellin A), nitrogen mustard (such as phenoxyethanol), phenoxyethanol, succinate, phenoxyethanol, succinate-binding peptide (such as phenoxyethanol), ... mustards (cyclophosphamide, ifosfamide, trofosfamide, chlorambucil, estramustine, and melphalan), nitrosoureas (carmustine and lomustine), alkylsulphonates (busulfan and treosulfan), triazenes (dacarbazine and temozolomide), platinum compounds (cisplatin, carboplatin, and oxaliplatin), vinca alkaloids (vinca alkaloids (such as vincristine, vinblastine, vindesine, and vinorelbine), taxoids (such as paclitaxel and docetaxeal), epipodophyllin (such asSuch as etoposide, etoposide phosphate, teniposide, topotecan, 9-aminocamptothecin, camptoirinotecan, irinotecan, crisnatol and mytomycin C), anti-metabolites, DHFR inhibitors (such as methotrexate, dichloromethotrexate, trimetrexate and edatrexate), inosine-5'-monophosphate dehydrogenase inhibitors (IMP dehydrogenase inhibitors (such as mycophenolic acid, tiazofurin, ribavirin and EICAR)), ribonucleotide reductase inhibitors (ribonucleotide reductase inhibitors). inhibitors, such as hydroxyurea and deferoxamine), uracil analogs (such as 5-fluorouracil (5-FU), floxuridine, doxifluridine, ratitrexed, tegafur-uracil, and capecitabine), cytosine analogs (such as cytarabine, ara C, cytosine arabinoside, and fludarabine), purine analogs (such as mercaptopurine and thioguanine), vitamin D3 analogs (such as EB 1089, CB 1093, and KH 1060), isoprenylation inhibitors, and inhibitors (e.g., lovastatin), dopaminergic neurotoxins (e.g., 1-methyl-4-phenylpyridinium ion), cell cycle inhibitors (e.g., staurosporine), actinomycin (e.g.,Such as actinomycin D), bleomycins (such as bleomycin A2, bleomycin B2 and peplomycin), anthracyclines (such as daunorubicin, doxorubicin, idarubicin, epirubicin, pirarubicin, zorubicin and mitoxantrone), multidrug resistance inhibitors (MDR inhibitors, such as verapamil), calcium ion ATPase inhibitors (Ca, 2+ATPase inhibitors (such as thapsigargin), imatinib, thalidomide, lenalidomide, tyrosine kinase inhibitors Kinase inhibitors, such as axitinib, bosutinib, cediranib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, lestaurtinib, neratinib, nilotinib, semaxanib, sunitinib, toceranib, vandetanib, vatalanib, rituximab, sorafenib, everolimus, temsirolimus, protease inhibitors (such as bortezomib), mammalian target protein inhibitors (mTOR inhibitors,For example, rapamycin, temsirolimus, everolimus, and rapamycin derivatives (ridaforolimus), oblimersen, gemcitabine, carminomycin, leucovorin, pemetrexed, cyclophosphamide, dacarbazine, procarbizine, prednisolone, dexamethasone, camptothecin, in), plicamycin, asparaginase, aminopterin, methotrexate, porfiromycin, melphalan, leurosidine, leurosine, chlorambucil, trabectedin, procarbazine, discodermolide, carminomycin, aminopterin or hexamethyl melamine. According to a specific embodiment of the present disclosure, the cytotoxic drug is mertansine, auristatin, maytansine, doxorubicin, calicheamicin or camptothecin. ,

[0144] Non-limiting examples of TLR agonists include: lipoteichoic acid, glucan, motolimod, imiquimod, resiquimod, gardiquimod, CpG oligodeoxynucleotide (CpG DON), lipopolysaccharide (LPS), monophosphoryl lipid A, and zymosan.

[0145] In various embodiments, the chelating agent can be selected from the group consisting of the following substances: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), N,N″-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N″-diacetic acid (HBED-CC), 1,4,7-triazacyclononane-1,4,7-triacetic acid (HBED-CC), acid, NOTA), 2-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl)pentanedioic acid, NODAGA), 2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanedioic acid, DOTAGA), 1,4,7-triazacyclononane phosphinic acid acid, TRAP), 1,4,7-triazacyclononane-1-[methyl(2-carboxyethyl)phosphinic acid]-4,7-bis[methyl(2-hydroxymethyl)phosphinic acid], NOPO), 3,6,9,15-tetraazabicyclo[9.3.1.]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid (3,6,9,15-tetraazabicyclo[9.3.1.]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid, PCTA), N'{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino]pentyl]-N-hydroxysuccinamide (N'{5-[Acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N- hydroxysuccinamide, DFO), diethylenetriaminepentaacetic acid (DTPA), trans-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-DTPA), 1-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid (1-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid acid, oxo-Do3A), p-isothiocyanatobenzyl-DTPA (SCN-Bz-DTPA), 1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M), 2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B) and 1-(2)-methyl-4-isocyanatobenzyl-DTPA (1-(2)-methyl-4-isocyanatobenzyl-DTPA, MX-DTPA). In certain embodiments, the radionuclide is. 111 In, 131 I or 177 Lu, in other embodiments, the radionuclide can be 90 Y. 68 Ga, 99m Tc, 64 Cu, 153 Gd, 155 Gd, 157 Gd, 213 Bi, 225 Ac or Fe.

[0146] In other embodiments, the selection of effector elements of the molecular construct of the present invention also covers a variety of polypeptide molecules, including (1) antibody fragments specific to inflammatory cytokines (such as TNF-α, IL-12 / IL-23, IL-17, IL-1, IL-6, BAFF), (2) antibody fragments specific to RANKL, (3) antibody fragments specific to CD3 and CD16a expressed on T cells and NK cells, (4) antibody fragments specific to PD-1, PD-L1, CTLA-4 and other immune checkpoint proteins, and (5) immune-enhancing cytokines (IFN-α, IFN-γ, IL-2, TNF-α).

[0147] The target elements suitable for the embodiments of the present disclosure can be selected depending on the disease to be treated. For example, the target elements for treating various diseases include (1) antibody fragments specific for components of the extracellular matrix in joints, skin or bones, such as type I collagen, type II collagen, type III collagen, type V collagen, type VII collagen, type IX collagen, type XI collagen, α-proteoglycan and osteonectin; (2) antibody fragments specific for a cluster of differentiation markers, such as CD19, CD20, CD22, CD30, CD52, CD79a, CD79b; CD38 , CD56, CD74, CD78 and CD138; or CD319, CD5, CD4, CD7, CD8, CD30; or CD13, CD14, CD15, CD33, CD34, CD36, CD37, CD41, CD61, CD64, CD65 and CD11c; and other cell surface antigens of lymphoid cell lines, myeloid cell lines and plasma cells, or (3) antibody fragments specific for receptors or antigens overexpressed on the surface of solid tumor cells, such as HER1, HER2 / Neu, HER3, Tn, Globo H, GD-2, CA125, CA19-9, and CEA.

[0148] Tumor cells or other diseased cells express certain hormones, growth factors or cytokines receptors, so the target element can also be an antibody to such hormones, growth factors or cytokines. In other optional embodiments, the target element of the molecular construct proposed herein is a growth factor.

[0149] According to certain embodiments of the present disclosure, at least one of the parent polypeptide and the functional element of the present disclosure is an antibody fragment specific for a growth factor. In certain embodiments, the growth factor is selected from the group consisting of the following substances: EGF, mutant EGF, epiregulin, HB-EGF, VEGF-A, bFGF and HGF. Similar to the concept described above, when the target element is a growth factor (e.g., EGF), the molecular construct proposed herein can specifically target cells / tissues / organs expressing the relevant receptors (e.g., tumor cells on which EGF receptors are expressed). When the effector element is an antibody fragment specific for a growth factor (e.g., VEGF-A), it can capture and neutralize the information transduction pathway associated with the growth factor (e.g., VEGF-A-induced angiogenesis). According to one embodiment, the molecular construct of the present invention can be used to treat solid tumors, wherein the effector element is an antibody fragment specific for VEGF-A.

[0150] Examples of pharmacokinetic elements include C8-28 fatty acid derivatives or C8-28 dibasic fatty acid derivatives. Each pharmacokinetic element is linked to a K residue via the ε-amino group of the K residue. According to various embodiments of the present disclosure, the functional element is a fatty acid derivative derived from octanoic acid, pelargonic acid, decanoic acid, undecanoic acid, lauric acid, tridecanoic acid, myristic acid, pentadecanoic acid, palmitic acid, margaric acid, stearic acid, nonadecanoic acid, arachidic acid, heneicosanoic acid, behenic acid, tricosanoic acid, lignoceric acid, palmitoleic acid, oleic acid, lionleic acid, ricinoleic acid, vaccenic acid, eicosapentaenoic acid, and succinic acid. According to certain embodiments of the present disclosure, the functional element is a dibasic fatty acid derivative derived from: 1,8-suberic acid, 1,7-azelaic acid, 1,10-undecanedioic acid, dodecanedioic acid, brassylic acid, sebacic acid, tetradecanedioic acid, pentadecanedioic acid, thapsic acid, heptadecanedioic acid or octadecanedioic acid. In certain embodiments, the functional element proposed herein is derived from myristic acid or palmitic acid. In other embodiments, the functional element proposed herein is derived from tetradecanedioic acid or hexadecanedioic acid.

[0151] (IV) Binding unit for coupling to a composite polypeptide having a metal binding domain

[0152] In certain embodiments adopted as needed, the functional element coupled to the above-mentioned composite polypeptide is presented in the form of a molecular beam (or a junction unit). According to certain embodiments of the present disclosure, the junction unit comprises a central core and a plurality of target elements, effector elements or pharmacokinetic elements. It is understood that such a junction unit also falls within the scope of protection of the present disclosure.

[0153] According to certain embodiments of the present disclosure, the binding unit comprises a central core and a plurality of elements, effector elements or pharmacokinetic elements as described in the above embodiments / implementations.

[0154] Specifically, the central core is a polypeptide having a length of 3-120 amino acid residues and comprising at least two lysine (K) residues; for example, the central core proposed herein may comprise 2, 3, 4, 5, 6, 7, 8, 9 or 10 K residues. According to certain embodiments, any two K residues may be adjacent to each other or separated by a filler. In certain examples, an SH-reactive group is connected to the first or last K residue of the central core by forming an amide bond therewith. In other examples, the central core further comprises a terminal spacer, and the SH-reactive group is connected to the terminal amino acid residue of the terminal spacer by forming an amide bond therewith. In this way, the terminal SH-reactive group of the junction unit proposed herein and the SH group of the cysteine ​​residue of the metal binding domain in the composite polypeptide can be coupled under appropriate conditions where the cysteine ​​residues of the parent polypeptide are mostly unreactive, thereby achieving position-specific coupling and obtaining a homogeneous molecular construct.

[0155] The terminal spacer can be an N-terminal spacer connected to the N-terminus of the first K residue, or a C-terminal spacer connected to the C-terminus of the last K residue. The filler and the terminal spacer independently contain at least: (1) 1 to 12 non-K amino acid residues, or (2) a PEGylated amino acid having 2 to 12 EG repeating units.

[0156] In the case where the junction unit does not have a connecting arm, each target element, effector element or pharmacokinetic element is connected to the K residue of the central core by forming an amide bond with the ε-amino group of the K residue. On the other hand, when the junction unit of the molecular construct further comprises 2 to 10 connecting arms, one end of each connecting arm is connected to the K residue of the central core by forming an amide bond with the ε-amino group of the K residue of the central core, and the other end of each connecting arm is connected to each target element, effector element or pharmacokinetic element. For example, the connecting arm can be a polypeptide comprising 2-12 non-K amino acid residues, or a pegylated amino acid chain having 2 to 24 EG repeating units.

[0157] According to the embodiments adopted as needed in the present disclosure, before coupling with the target element, effector element or pharmacokinetic element, the free end of the linker (i.e., the end not connected to the central core lysine residue) may carry a linker selected from the group consisting of amino, carboxyl, hydroxyl, NHS, azido, alkynyl, cyclooctyne, tetrazine or cyclooctenyl. Depending on the linker (i.e., amino, carboxyl, NHS, azido, alkynyl, cyclooctyne, tetrazine or cyclooctenyl) that modifies the side chain amino group of the lysine residue (in the absence of a linker), or depending on the linker appearing at the free end of the linker, a functional element (e.g., a target element, a therapeutic effector element or an element capable of improving pharmacokinetic properties) with a corresponding functional group can be designed, so that the functional element can be connected to the linker through any of the following chemical reactions:

[0158] (1) forming an amide bond therebetween: in this case, the linking group is an amino group, a carboxyl group or an NHS group, and the functional element has an amino group or a carboxyl group;

[0159] (2) Copper (I)-catalyzed alkyne-azidecycloaddition (CuAAC) reaction: one of the linker and the functional element carries an azide or picolyl azide group, and the other carries an alkyne group;

[0160] (3) inverse electron demand Diels–Alder (iEDDA) reaction: one of the linker and the functional element has a tetrazine group, while the other has a cyclooctenyl group (e.g., TCO or norbornene group); or

[0161] (4) Strain-promoted azide-alkyne clickchemistry (SPAAC): One of the linker and the functional element carries an azide group, while the other carries a cyclooctyne group.

[0162] According to various embodiments of the present disclosure, the tetrazine group is 1,2,3,4-tetrazine, 1,2,3,5-tetrazine, 1,2,4,5-tetrazine or derivatives thereof; the cyclooctenyl group is norbornene or trans-cyclooctene (TCO); and the cyclooctyne group is selected from the group consisting of dibenzocyclooctyne (DIBO), difluorinated cyclooctyne (DIFO), bicyclononyne (BCN) and dibenzoazacyclooctyne (DIBAC or DBCO). According to one embodiment of the present disclosure, the tetrazine group is 6-methyl-tetrazine.

[0163] According to certain optional embodiments of the present disclosure, the central core carries a local negative charge at or near the amino acid residue linked to the SH-reactive group. For example, the local negative charge appears at the first 5 to 15 amino acid residues from the amino acid residue linked to the SH-reactive group. Specifically, the local negative charge appears in the first 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acid residues from the amino acid residue linked to the SH-reactive group. The local negative charge can be formed by one or more amino acid residues that carry a negative charge at pH = 7, such as aspartic acid (D) and glutamic acid (E) residues.

[0164] Alternatively, the central core may be coupled to a plurality of negatively charged effector elements so that the central core has a local negative charge at or near the SH-reactive group. For example, the effector element may be a chelating agent (e.g., DOTA, DOTAGA, and the like) that increases the overall net negative charge of the binding unit.

[0165] The targets, effects and pharmacokinetic elements described above with reference to Section (III) are also applicable to the embodiments described in Section (IV), and are not described here for brevity. In various embodiments, a conjugated unit carrying a plurality of effector elements is called an "effector molecule bundle" or a "drug-carrying bundle"; a conjugated unit carrying a plurality of chelators is called a "chelator bundle"; a conjugated unit carrying a plurality of target elements is called a "target molecule bundle"; a conjugated unit carrying a plurality of scFvs is called a "scFv bundle"; a conjugated unit carrying a plurality of pharmacokinetic elements is called a "pharmacodynamic molecule bundle" or a "PK bundle"; and a conjugated unit carrying a plurality of fatty acid chains and / or dibasic fatty acid chains is called a "fatty acid bundle" or a "FA bundle".

[0166] In certain embodiments, a fatty acid (or dibasic fatty acid) derivative is a chemically modified fatty acid (or dibasic fatty acid) molecule. For example, the carboxyl group of a fatty acid molecule (or one of the carboxyl groups of a dibasic fatty acid molecule) can react with a chemical entity having two functional groups, one of which can react with the carboxyl group, thereby forming a covalent bond with the (dibasic) fatty acid molecule; and the other functional group can react with the side chain amino group of a lysine residue. According to the embodiments adopted as needed in the present disclosure, the chemical entity that modifies the (dibasic) fatty acid molecule is a glutamic acid residue, an aspartic acid residue, an amino-EG2-acid, a gamma-aminobutyric acid, or the like; however, the present disclosure is not limited thereto.

[0167] It can be understood that when the parent polypeptide does not contain a cysteine ​​residue or other sulfhydryl-containing amino acid residue, a terminal cysteine ​​residue can be introduced to replace the terminal metal binding domain to obtain a composite polypeptide, and the conjugation unit proposed herein can form a conjugate with the composite polypeptide through this terminal cysteine ​​residue.

[0168] (V) A junction unit having a plurality of composite polypeptides with metal binding domains

[0169] Yet another embodiment of the present disclosure is a junction unit, which carries a plurality of composite polypeptides as shown in the above embodiments / implementations of the present disclosure. In certain embodiments, such a junction unit is also referred to as a "polypeptide bundle".

[0170] According to certain embodiments of the present disclosure, the junction unit comprises a central core, 2 to 10 connecting arms, and 2 to 10 composite polypeptides as described in the above embodiments / implementations. The free end of the connecting arm of such a junction unit carries an SH-reactive group, and since each composite polypeptide carries the metal binding domain as proposed herein, the composite polypeptide can be coupled to the connecting arm in a position-specific manner under appropriate conditions where the cysteine ​​residues of the parent polypeptide are mostly unreactive.

[0171] Specifically, the central core is a polypeptide having a length of 3-120 amino acid residues and comprising at least two lysine (K) residues, for example, the central core proposed herein may comprise 2, 3, 4, 5, 6, 7, 8, 9 or 10 K residues. According to certain embodiments, any two K residues may be adjacent to each other or separated by a filler.

[0172] In some cases, the central core further comprises a complexing group, which is connected to the first or last K residue of the central core by forming an amide bond therewith. Examples of complexing groups include, but are not limited to, azido, alkynyl, tetrazine, cyclooctenyl and cyclooctynyl.

[0173] In other examples, the central core further comprises a terminal spacer, and the SH-reactive group is connected to the terminal amino acid residue of the terminal spacer by forming an amide bond therewith. The terminal spacer can be an N-terminal spacer connected to the N-terminus of the first K residue, or a C-terminal spacer connected to the C-terminus of the last K residue.

[0174] The filler and the terminal spacer independently comprise at least: (1) 1 to 12 non-K amino acid residues, or (2) a PEGylated amino acid having 2 to 12 EG repeating units. Generally speaking, the spacer can be (1) a polypeptide consisting of 1-12 (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) amino acid residues other than K amino acid residues, or (2) a PEGylated amino acid having 1-12 (i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) EG units. Specifically, when the central core proposed herein comprises at least a plurality of K residues, the spacer may comprise a PEGylated amino acid having 2-12 EG units, or may comprise 1-12 non-K amino acid residues, wherein each non-K amino acid residue is individually and independently selected from the group consisting of glycine (G), aspartic acid (D), glutamic acid (E), serine (S), arginine (R), histidine (H), threonine (T), asparagine (N), glutamine (Q), proline (P), alanine (A), valine (V), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), tyrosine (Y) and tryptophan (W) residues; in a preferred case, each non-K amino acid residue is individually and independently selected from the group consisting of G, S, R, H, T, N, Q, P, A, V, I, L, M, F, Y and W residues; in a more preferred case, each non-K amino acid residue is a G and / or S residue.

[0175] According to some embodiments, one end of each linker is connected to the K residue of the central core by forming an amide bond with the ε-amino group of the K residue of the central core, and the other end of each linker carries a sulfhydryl (SH)-reactive group. For example, the linker can be a polypeptide comprising 2-12 non-K amino acid residues, or a PEGylated amino acid chain having 2 to 24 EG repeating units.

[0176] Exemplary SH-reactive groups include maleimide, haloacetyl (e.g., iodoacetyl or bromoacetyl), sulfone (e.g., vinylsulfone, monosulfone, methylsulfonylbenzothiazolyl), and pyridyldisulfide (e.g., 2-pyridyldithiol).

[0177] According to certain embodiments of the present disclosure, the linker is a polypeptide comprising at least 2-12 (i.e., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) non-K amino acid residues (each of which may be a natural or non-natural amino acid residue). For example, the linker is a polypeptide comprising at least 2-12 non-K amino acid residues (i.e., amino acid residues independently selected from the following groups: G, E, D, S, R, H, T, N, Q, P, A, V, I, L, M, F, Y and W residues). According to one embodiment, the linker provided herein is a polypeptide comprising at least 5-10 amino acid residues independently selected from G, S, E and R residues. Alternatively, the linker can be a PEG chain with 2-24 (i.e., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24) EG repeating units; preferably, 5-15 EG repeating units; more preferably, 6-12 EG repeating units. It will be appreciated that polymers of substantially the same length may be used in place of the linker polypeptides or PEG chains described herein. Polymers such as carbohydrates or other hydrophilic structural units may be used as linkers.

[0178] According to some embodiments of the present disclosure, each connecting arm carries a local negative charge at or near the amino acid residue connected to the SH-reactive group. Specifically, the local negative charge appears at the first 5 to 15 amino acid residues from the amino acid residue connected to the SH-reactive group. For example, the local negative charge appears in the first 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acid residues from the amino acid residue connected to the SH-reactive group. The local negative charge can be formed using one or more amino acid residues that carry a negative charge at pH = 7 (such as aspartic acid (D) and glutamic acid (E) residues).

[0179] It can be understood that when the central core proposed herein comprises at least two terminal spacers or fillers, each terminal spacer or filler may be the same or different; that is, each terminal spacer or filler may comprise the same or different amino acid sequences and / or EG units. According to one embodiment of the present disclosure, the central core proposed herein comprises three fillers, wherein the first filler is a PEGylated amino acid having 8 EG units, and the other two fillers are one S residue and one G residue, respectively. According to another embodiment of the present disclosure, the central core proposed herein comprises one terminal spacer and four fillers, wherein one terminal spacer consists of four G residues and two S residues, and the other four fillers each consist of one G residue and one S residue. According to yet another embodiment of the present disclosure, the central core proposed herein comprises two terminal spacers and three fillers, each of which is a PEGylated amino acid having four EG units.

[0180] According to an optional embodiment of the present invention, a joining unit (or polypeptide bundle) comprising a plurality of composite polypeptides can be coupled to an additional joining unit, for example, by reacting with the complexing group of the central core to form a molecular construct. For example, the additional joining unit can be an effector molecule beam, a target molecule beam or a PK beam. For example, the structure of the additional joining unit is similar to the structure described in the application previously filed by the applicant. In short, the structure of this additional joining unit can be similar to that described in Section (III) above, except that the terminal SH-reactive group is replaced with a corresponding complexing group that can react with the complexing group of the polypeptide.

[0181] When the target or effector element carried by the additional binding unit is a polypeptide element, the polypeptide element may also have the zinc binding domain mentioned above, and the additional binding unit may adopt the structure of the polypeptide bundle mentioned here, thereby obtaining a molecular construct composed of two polypeptide bundles carrying different functional elements.

[0182] In certain optional embodiments, the complexing group is part of a complexing moiety having a functional group capable of bonding to the α-amino group (—NH 2) or the carboxyl group (-COOH) of the terminal amino acid residue (i.e., the last connecting amino acid residue or the C-terminal amino acid residue of the C-terminal spacer) to form a covalent bond to connect the composite part to it. In some embodiments, the central core may have only one of the N-terminal and C-terminal spacers, and the first and second composite parts are respectively connected to the two terminal amino acid residues (which can be the terminal connecting amino acid residues or the terminal amino acid residues of the terminal spacer). In some embodiments, the central core comprises both the N-terminal and C-terminal spacers, and the two composite parts are respectively connected to the terminal amino acid residues of the two terminal spacers. In a preferred embodiment, the covalent bond formed between the composite part and the terminal amino acid residue is an amide bond. It will be understood that in order to ensure that a homogeneous molecular beam can be obtained, the functional group on a composite part can only react with one of the α-amino group or the carboxyl group.

[0183] Optionally, the composite portion may further comprise a PEG chain having 2-10 (i.e., 2, 3, 4, 5, 6, 7, 8, 9 or 10) EG repeats to link the carboxyl or amino group and the composite group together; for example, the PEG chain may have 4, 6, 7 or 8 EG units.

[0184] According to various embodiments of the present disclosure, the two composite parts may have the same or different reactivity. Preferably, when the second composite group of the composite part is an azido group, an alkynyl group or a cyclooctyne group, the linking group of the connecting arm cannot be an azido group, an alkynyl group or a cyclooctyne group to avoid reaction between the second composite group and the linking group; in this case, the linking group can be a tetrazine group, a cyclooctenyl group, an amino group, a carboxyl group, or an NHS group. Alternatively, when the second composite group is a tetrazine group or a cyclooctenyl group, the linking group cannot be a tetrazine group or a cyclooctenyl group; in this case, the linking group can be an azido group, an alkynyl group, a cyclooctyne group, an amino group, a carboxyl group, or an NHS group.

[0185] It is understood that the number of optional connecting arms connected to the central core depends on the number of connecting amino acid residues (i.e., K residues) in the central core. Since there are at least two connecting amino acid residues in the central core proposed herein, the target or effector molecule bundle proposed herein may include multiple connecting arms.

[0186] It will be understood that the above statements with respect to effector, target or pharmacokinetic elements apply to all embodiments / implementations involving such elements unless the context indicates otherwise.

[0187] It is understood that, in the solid-state synthesis of the polypeptide core, in addition to attaching the functional elements after the synthesis of the core, K amino acid residues modified with specific functional elements can also be added to the polypeptide chain being synthesized. Therefore, according to various embodiments, K residues modified with different functional elements can be added sequentially during the solid-state synthesis process to obtain a homogeneous PK bundle, wherein each PK bundle can contain two or more different functional elements attached thereto.

[0188] A number of examples are presented below to illustrate certain embodiments of the present invention, so as to facilitate the practice of the present invention by those skilled in the art. These examples are merely illustrative and should not be construed as limiting the scope of the present invention. It is believed that after reading the description presented herein, one of ordinary skill in the art can fully utilize and practice the present invention without over-interpreting the present invention.

[0189] Example

[0190] Example 1

[0191] Synthesis of the central core of Mal-peptide 1

[0192] In this example, the inventors of the present invention designed a polypeptide with five lysine residues and commissioned it to be synthesized by KareBay Co., Ltd. (Monmouth Junction, USA). This polypeptide can be used as a central core to construct a junction unit or a functional molecular bundle. Mal-peptide 1 (maleimide ethyl GGSGGSKGSKGSKGSKGSK; SEQ ID NO: 11) was synthesized using standard Fmoc solid-state synthesis. The purity of Mal-peptide 1 was 95.67%.

[0193] The synthesized peptides were confirmed by mass spectrometry MALDI-TOF analysis. Mass spectrometry analysis was performed at the mass spectrometry core facility of the Institute of Molecular Biology, Academia Sinica (IMB, Taiwan, China). The equipment used was a Bruker AutoflexIII MALDI-TOF / TOF mass spectrometer (Bruker Daltonics, Bremen, Germany).

[0194] Figure 1 This is the result of MALDI-TOF mass spectrometry analysis. It can be seen from the figure that the molecular weight of Mal-peptide 1 is 1,790.916 Daltons.

[0195] Example 2

[0196] Synthesis of Mal-peptide 2-DOTA bundles

[0197] In this embodiment, the chelating agent bundle designed by the inventors of the present invention (see Figure 2 ) is a maleimide-containing polypeptide with three lysine residues as the central core, and three DOTA molecules are coupled to the central core (Mal-peptide 2-DOTA bundle). This chelator bundle was synthesized by KareBay Co., Ltd. (Monmouth Junction, USA).

[0198] Mal-peptide 2 (maleimidoethyl GGSGGSGKGGSGGSGKGGSGGSGK, SEQ ID NO: 12) was synthesized using standard Fmoc solid-state synthesis, and then the DOTA molecule was coupled to the central core using liquid-state synthesis.

[0199] Purified samples of the synthesized chelator bundle were analyzed by reverse phase high performance liquid chromatography (HPLC) using a Supelco C18 column (250 mm×4.6 mm; 5 μm) with acetonitrile and 0.1% trifluoroacetic acid as the mobile phase, a linear gradient of acetonitrile from 0% to 100% in 30 min, a flow rate of 1.0 ml / min and a column temperature of 35°C. Figure 3A This is a reverse phase HPLC spectrum of the chelating agent bundle of Example 2, which shows that the peak of the chelating agent bundle can be observed at a retention time of 7.06 minutes.

[0200] The synthesized Mal-peptide 2-DOTA bundle was confirmed by mass spectrometry MALDI-TOF analysis. Figure 3B The results of MALDI-TOF mass spectrometry analysis showed that the molecular weight of the chelator bundle presented here was 3,093.454 Daltons.

[0201] Example 3

[0202] Construction, expression and purification of recombinant double-chain (scFvαCD19)-Fc-MBM-1

[0203] V of scFv specific for human CD19 L and V H The gene sequence encoding the scFv-CH2-CH3 (human γ1) recombinant chain from the monoclonal antibody RB4v1.2 was constructed as follows: the gene sequence encoding the scFv specific for human CD19 was inserted into the upstream position of the flexible hinge region and CH2 domain of IgG1.Fc, and the gene sequence encoding the metal binding domain (MBM)-1, i.e., ACPGHA sequence (SEQ ID NO: 7), was inserted into the downstream position of the CH3 domain of IgG1.Fc and a short flexible linker GGGG (SEQ ID NO: 9).

[0204] The scFv was constructed in two orientations, namely, V L- Joint-VH and V H- Joint-V L , where V L and V H The V of (scFvαCD19)-Fc-MBM-1 proposed herein is connected via a hydrophilic conjugate, the sequence of which is GSTSGSGKPGSGEGSTKG (SEQ ID NO: 10). L- Joint-V H and V H- Joint-V L The amino acid sequences of the recombinant chains are shown in SEQ ID NOs: 13 and 14, respectively, and Figure 4A The general structure of the double-chain (scFvαCD19)-Fc-MBM-1 molecular constructs is disclosed.

[0205] When using mammalian expression systems to produce recombinant proteins, the Expi293F TM Cell-based overexpression system. The system used uses ExpiFectamine TM 293 transfection kit (Life Technologies, Carlsbad, USA), which contains Expi293F TM Cell line, cationic lipid is ExpiFectamine TM 293 reagent, ExpiFectamine TM 293 Transfection Enhancers 1 and 2, and culture medium (Gibco, New York, USA).

[0206] The gene encoding sequence was placed in a pcDNA3 expression cassette. Expi293F cells were cultured at 2.0 × 10 6 The cells were seeded at a density of 10 viable cells in Expi293F expression medium and maintained for 18 to 24 hours before transfection to ensure that the cells were in a dividing state when transfection was performed. 8 255 ml of culture medium for 10 cells was placed in a 2-L Ehrlich flask and ExpiFectamine was added. TM 293 transfection reagent. After transfection, the transfected cells were incubated at 37°C with an orbital shaker (125 rpm) for 16 to 18 hours; then ExpiFectamine TM 293 cells were transfected with Booster 1 and Booster 2 and cultured for 5 to 6 days. The culture supernatant was collected and the hIgG1.Fc fusion recombinant protein in the culture medium was purified by protein A affinity chromatography.

[0207] The buffer was replaced with PBS, and then the concentration of (scFvαCD19)-Fc-MBM-1 proposed here was determined and analyzed by 10% SDS-PAGE. The analysis results showed that the molecular weight of (scFvαCD19)-Fc-MBM-1 proposed here was about 120 kDa on non-reducing SDS-PAGE, which was slightly larger than the expected molecular weight of 110 kDa. Figure 4B For double chain (V L -V H The non-reducing SDS-PAGE analysis results of scFvαCD19)-Fc-MBM-1 are shown in the main band indicated by the arrow. It should be understood that the SDS-PAGE results are only used to quickly confirm the approximate molecular weight of the synthesized molecular construct, and mass spectrometry analysis can be used to determine a more accurate molecular weight. For example, the MALDI-TOF analysis results of the molecular constructs proposed herein are shown in Fig.23 shown.

[0208] Example 4

[0209] Construction, expression and purification of recombinant double-chain (scFvαCD19)-Fc-MBM-2

[0210] In this example, V was constructed, expressed and purified in a similar manner to the above examples. L- Joint-V H The difference is that a different metal binding domain is used here, and its sequence is GCPGHA (SEQ ID NO: 8, hereinafter referred to as MBM-2). L -V H The amino acid sequence of the recombinant chain of scFvαCD19)-Fc-MBM-2 is shown in SEQ ID NO:15.

[0211] Figure 5 The SDA-PAGE results showed that the recombinant chain size of the molecular construct proposed here was about 120 kDa (indicated by the arrow), which was slightly larger than the expected size.

[0212] Example 5

[0213] Construction, expression and purification of recombinant double-chain (scFvαCD19)-Fc-MBM-3

[0214] In this example, V was constructed, expressed and purified in a similar manner to the above examples. L- Joint-V HThe difference is that a different metal binding domain is used here, and its sequence is GCGGHA (SEQ ID NO: 6, hereinafter referred to as MBM-3). L- Joint-V H The amino acid sequence of the configured (scFvαCD19)-Fc-MBM-3 recombinant chain is shown in SEQ ID NO:16.

[0215] SDS-PAGE was used to identify L -V H scFvαCD19)-Fc-MBM-3 molecular construct. Figure 6 The SDA-PAGE results showed that the size of the recombinant chain of this new molecular construct was about 110 kDa (as indicated by the arrow), which was consistent with the expected size.

[0216] Example 6

[0217] Construction, expression and purification of recombinant anti-CD19 antibody-MBM

[0218] A short flexible linker GGGG (SEQ ID NO: 9) and MBM sequence (in this example, MBM-1 or MBM-2) were attached to the C-terminus of the heavy chain of a complete antibody specific for C19 to construct a recombinant IgG (human γ1) molecule construct. The above gene sequence was inserted into a pG1K expression cassette with multiple cloning sites. The recombinant anti-CD19 antibody-MBM presented herein was expressed and purified in a manner similar to the above examples.

[0219] The amino acid sequences of the heavy chain of the human CD19 specific antibody, MBM-1 or MBM-2, are shown in SEQ ID NOs: 17 and 18, respectively, and the amino acid sequence of the light chain of the full-length anti-CD19 antibody is shown in SEQ ID NO: 19.

[0220] SDS-PAGE was used to identify the molecular construct. Fig. 7A The reducing SDA-PAGE results showed that the control protein (electrophoresis lane 1), human CD19 antibody-MBM-1 (electrophoresis lane 2) and human CD19 antibody-MBM-2 (electrophoresis lane 3) had a larger molecular weight band of about 55 kDa and a smaller molecular weight band of about 25 kDa, which were consistent with the expected sizes of the heavy chain and light chain of the present molecular construct, respectively.

[0221] The general structure of the anti-CD19 antibody-MBM-1 molecular construct is as follows Figure 7B shown.

[0222] Example 7

[0223] Construction, expression and purification of recombinant double-chain (scFvαCD33)-Fc-MBM

[0224] V of scFv specific for human CD33 L and V H The gene sequence encoding the (scFvαCD33)-CH2-CH3 (human γ1) recombinant chain from the monoclonal antibody huMy9-6 was constructed as follows: the gene sequence encoding the scFv specific for human CD33 was inserted into the upstream position of the flexible hinge region and CH2 domain encoding IgG1.Fc, and the gene sequence encoding MBM-1 or MBM-2 was inserted into the downstream position of the CH3 domain encoding IgG1.Fc and a short flexible linker GGGG (SEQ ID NO: 9).

[0225] The scFv was constructed in two orientations, namely, V L- Joint-V H and V H- Joint-V L , where V L and V H The V of (scFvαCD33)-Fc-MBM-1 proposed herein is connected via a hydrophilic conjugate, the sequence of which is GSTSGSGKPGSGEGSTKG (SEQ ID NO: 10). L- Joint-V H and V H- Joint-V L The amino acid sequences of the recombinant chains are shown in SEQ ID NOs: 20 and 21, respectively, and the V L- Joint-V H and V H- Joint-V L The amino acid sequences of the configured recombinant chains are shown in SEQ ID NOs: 22 and 23, respectively.

[0226] The recombinant double-chain (scFvαCD33)-Fc-MBM presented here was expressed and purified in a manner similar to the above example.

[0227] Non-reducing SDS-PAGE was used to identify the molecular construct. Figure 8 The SDA-PAGE results showed that (V L -V H scFvαCD33)-Fc-MBM-1 (electrophoresis strip 1), (V H -V L scFvαCD33)-Fc-MBM-1 (electrophoresis strip 2), (VL -V H scFvαCD33)-Fc-MBM-2 (electrophoresis lane 3) and (V H -V L scFvαCD33)-Fc-MBM-2 (electrophoresis lane 4) each had a band of approximately 120 kDa, slightly larger than the expected size of 110 kDa.

[0228] Example 8

[0229] Construction, expression and purification of recombinant double-chain (scFvαCD20)-Fc-MBM

[0230] V of scFv specific for human CD20 L and V H From ocrelizumab. The metal binding domains MBM-1, MBM-2 or MBM-3 were attached to the C-terminus of the CH3 domain of the (scFvαCD20)-CH2-CH3 (human γ1) recombinant chain through a short flexible linker GGGG (SEQ ID NO: 9). The scFv was constructed in two directions, i.e., V L- Joint-V H and V H- Joint-V L , where V L and V H It is connected via a hydrophilic linker, the sequence of which is GSTSGSGKPGSGEGSTKG (SEQ ID NO: 10).

[0231] The recombinant double-chain (scFvαCD20)-Fc-MBM-1, -MBM-2 or -MBM-3 proposed herein were expressed and purified in a manner similar to the above examples. L -V H scFvαCD20)-Fc-MBM-1, (V H -V L scFvαCD20)-Fc-MBM-1, (V H -V L scFvαCD20)-Fc-MBM-2, (V L -V H scFvαCD20)-Fc-MBM-3 and (V H -V L The sequences of the scFvαCD20)-Fc-MBM-3 recombinant chains are shown in SEQ ID NOs: 24, 25, 26, 27 and 28, respectively.

[0232] The recombinant double-chain (scFvαCD20)-Fc-MBM presented here was expressed and purified in a manner similar to the above examples.

[0233] Non-reducing SDS-PAGE was used to identify the molecular construct. Fig. 9 The SDA-PAGE results showed that (V L -V H scFvαCD20)-Fc-MBM-1 (electrophoresis lane 1) and (V H -V L The size of both molecular constructs, scFvαCD20)-Fc-MBM-1 (electrophoresis lane 2), was approximately 120 kDa, slightly larger than the expected size of 110 kDa. Fig. 10A and Fig. 10B The SDA-PAGE results showed that (V H -V L scFvαCD20)-Fc-MBM-2 and (V L -V H The sizes of both scFvαCD20)-Fc-MBM-3 molecular constructs were approximately 120 kDa, slightly larger than the expected size of 110 kDa.

[0234] Example 9

[0235] Construction, expression and purification of recombinant double-chain (scFvαCA19-9)-Fc-MBM

[0236] Mouse B cell fusion tumor cells HB8059 producing anti-CA19-9 antibodies were purchased from the Developmental Studies Hybridoma Bank of the University of Iowa. Poly(A)+ RNA was reverse transcribed using the SuperScript III RT-PCR system (Invitrogen, Waltham, USA) and the first strand cDNA was synthesized. H With V L The nucleotide and amino acid sequences of HB8059 have not been published previously. To determine the sequence of the variable region of HB8059, the V H With V L cDNA of HB8059 monoclonal antibody specific for human CA19-9 H and V L The amino acid sequences of the proteins are shown in SEQ ID NOs: 29 and 30, respectively.

[0237] MBM-1 or MBM-3 was connected to the C-terminus of the CH3 domain of the (scFvαCA19-9)-CH2-CH3 (human γ1) recombinant chain through a short flexible linker GGGG (SEQ ID NO: 9). The orientation of the scFv is V L- Joint-V H , where V L and V H It is connected via a hydrophilic conjugate, the sequence of which is GSTSGSGKPGSGEGSTKG (SEQ ID NO: 10). The sequences of the recombinant chains of (scFvαCA19-9)-Fc-MBM-1 and (scFvαCA19-9)-Fc-MBM-3 proposed herein are shown in SEQ ID NOs: 31 and 32, respectively.

[0238] The recombinant double-chain (scFvαCA19-9)-Fc-MBM presented here was expressed and purified in a manner similar to the above example.

[0239] SDS-PAGE was used to identify the molecular construct. Fig.11A and Fig. 11B The SDA-PAGE results showed that the size of the recombinant chains of the two molecular constructs (scFvαCA19-9)-Fc-MBM-1 and (scFvαCA19-9)-Fc-MBM-3 was about 120 kDa (electrophoresis lane 1), which was slightly larger than the expected size of 110 kDa.

[0240] Example 10

[0241] Construction, expression and purification of recombinant double-chain (scFvαCD38)-Fc-MBM

[0242] V of scFv specific for human CD38 L and V H Derived from daratumumab. The metal binding domains MBM-1 and MBM-2 were connected to the C-terminus of the CH3 domain of the (scFvαCD38)-CH2-CH3 (human γ1) recombinant chain through a short flexible linker GGGG (SEQ ID NO: 9). The scFv was constructed in two directions, namely, V L- Joint-V H and V H- Joint-V L , where V L and V HThe recombinant double-chain (scFvαCD38)-Fc-MBM-1 or -MBM-2 proposed herein was expressed and purified in a manner similar to the above examples. L -V H scFvαCD38)-Fc-MBM-1, (V H -V L scFvαCD38)-Fc-MBM-1, (V L -V H scFvαCD38)-Fc-MBM-2 and (V H -V L The sequences of the recombinant chains of scFvαCD38)-Fc-MBM-2 are shown in SEQ ID NOs: 33, 34, 35 and 36, respectively.

[0243] SDS-PAGE was used to identify the molecular construct. Fig. 12A The SDA-PAGE results showed that (V L -V H The size of the recombinant chain of scFvαCD38)-Fc-MBM-1 (electrophoresis lane 1) was approximately 120 kDa, slightly larger than the expected size of 110 kDa. Fig. 12B The SDA-PAGE results showed that (V L -V H The size of the scFvαCD38)-Fc-MBM-2 recombinant chain was approximately 120 kDa, slightly larger than the expected size of 110 kDa.

[0244] Embodiment 11

[0245] Preparation of recombinant double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle

[0246] In this example, a molecular construct was prepared, which had two DOTA bundles, coupled to the cysteine ​​residues of the metal binding domain of the double-chain (scFvαCD19)-Fc-MBM-1; Fig.13A The schematic structure of this molecular construct is shown. L -V HThe cysteine ​​residue at the C-terminus of scFvαCD19)-Fc-MBM-1 was incubated with 45 μM tris(2-carboxyethyl)phosphine (TCEP) in sodium succinate buffer (10 mM sodium succinate, pH 6.0 and 30 mM sucrose) for 30 minutes at room temperature with gentle shaking. After the reduction reaction, the protein was dialyzed against 10 mM sodium succinate buffer (pH 6.0 containing 30 mM sucrose) containing 60 μM Zn(II) ions to remove excess TCEP. Thereafter, the reduced protein sample was treated with 15 μM Mal-peptide 2-DOTA bundles of Example 2 and then incubated at room temperature for 1 hour. Unreacted DOTA bundles were removed using a desalting column, and the product was analyzed using SDS-PAGE.

[0247] Fig. 13B The SDS-PAGE analysis results of the molecular construct proposed herein show that the molecular weight of the molecular construct proposed herein is about 120 kDa (electrophoresis bar 2, as indicated by the arrow), which is slightly smaller than the expected size. Electrophoresis bar 1 is a sample of the uncoupled fusion protein. Fig. 13B As shown, the coupling yield of DOTA bundle with recombinant double-chain (scFvαCD19)-Fc-MBM-1 was about 90%. Image J was used to quantify the protein bands on SDS-PAGE.

[0248] Example 12

[0249] Preparation of recombinant double-chain (scFvαCD19)-Fc-MBM-2 X 2 DOTA bundle

[0250] In this example, two DOTA bundles were coupled to the recombinant double-stranded (V L -V H scFvαCD19)-Fc-MBM-2.

[0251] Fig.14 The SDS-PAGE analysis results of the molecular construct proposed herein show that the molecular weight of the molecular construct proposed herein is about 120 kDa (electrophoresis bar 2, as indicated by the arrow), which is consistent with or slightly smaller than the expected size. Electrophoresis bar 1 is a sample of the uncoupled fusion protein. Fig.14 As shown, the coupling yield of DOTA bundle to recombinant double-chain (scFvαCD19)-Fc-MBM-2 was about 90%.

[0252] Example 13

[0253] Preparation of recombinant double-chain (scFvαCD19)-Fc-MBM-3 X 2 DOTA bundle

[0254] In this example, two DOTA bundles were coupled to the recombinant double-stranded (V L -V H scFvαCD19)-Fc-MBM-3.

[0255] Fig.15 The SDS-PAGE analysis results of the molecular construct proposed herein show that the molecular weight of the molecular construct proposed herein is about 120 kDa (electrophoresis bar 2, as indicated by the arrow), which is consistent with or slightly smaller than the expected size. Electrophoresis bar 1 is a sample of the uncoupled fusion protein. Fig.15 As shown, the coupling yield of DOTA bundle to recombinant double-chain (scFvαCD19)-Fc-MBM-3 was about 90%.

[0256] Embodiment 14

[0257] Preparation of anti-CD19 antibody-MBM-1 X 2 DOTA bundles

[0258] In this example, two DOTA tracts were coupled to the full-length human anti-CD19 antibody of Example 6 with MBM-1 attached to the C-terminus using the method described in the previous examples.

[0259] Fig.16 The results of SDS-PAGE analysis of the anti-CD19 antibody-MBM-1 X 2 DOTA bundle molecule construct presented here. Fig.16 As shown, the molecular weight of the heavy chain is about 54 kDa (as shown by arrow #1 in electrophoresis strip 2), which is consistent with the expected size. Arrow #2 in electrophoresis strip 2 is the uncoupled heavy chain of anti-CD19 antibody-MBM-1, and arrow #3 is the light chain of anti-CD19 antibody-MBM-1.

[0260] Embodiment 15

[0261] Preparation of anti-CD19 antibody-MBM-2 X 2 DOTA bundles

[0262] In this example, two DOTA bundles were coupled to the full-length human anti-CD19 antibody of Example 6 with MBM-2 attached to the C-terminus using the method described in the above examples.

[0263] Fig.17 Results of SDS-PAGE analysis of the molecular constructs presented here. Fig.17 As shown, the molecular weight of the heavy chain is about 54 kDa (as shown by arrow #1 in electrophoresis strip 2), which is consistent with the expected size. Arrow #2 in electrophoresis strip 2 is the uncoupled heavy chain of anti-CD19 antibody-MBM-1, and arrow #3 is the light chain of anti-CD19 antibody-MBM-2.

[0264] Example 16

[0265] Preparation of recombinant double-chain (scFvαCD33)-Fc-MBM X 2 DOTA bundle

[0266] In this example, two DOTA bundles were coupled to the recombinant double-stranded (V L -V H scFvαCD33)-Fc-MBM-1 or –MBM-2.

[0267] Fig.18 The SDS-PAGE analysis results of coupling DOTA bundle to recombinant double-chain (scFvαCD33)-Fc-MBM-1. Fig.18 As shown, the molecular weight of the present molecular construct is about 120 kDa (as shown by arrow #1 in electrophoresis strip 2), which is consistent with or slightly smaller than the expected size. Arrow #2 in electrophoresis strip 1 is the uncoupled fusion protein. The results of SDS-PAGE analysis showed that the coupling yield of the DOTA bundle with the recombinant double-chain (scFvαCD33)-hIgG1.Fc–MBM-1 was about 65%.

[0268] Embodiment 17

[0269] Preparation of recombinant double-chain (scFvαCD20)-Fc-MBM-1 X 2 DOTA bundle

[0270] In this example, two DOTA bundles were coupled to the recombinant double-stranded (V L -V H scFvαCD20)-Fc-MBM-1.

[0271] Fig.19 The SDS-PAGE analysis results of coupling DOTA bundle to recombinant double-chain (scFvαCD20)-Fc-MBM-1. Fig.19 As shown, the molecular weight of the present molecular construct is about 120 kDa (as shown by arrow #1 in electrophoresis strip 2), which is consistent with or slightly smaller than the expected size. Arrow #2 in electrophoresis strip 1 is the uncoupled fusion protein. Fig.19 The results of SDS-PAGE analysis showed that the coupling yield of DOTA bundle and recombinant double-chain (scFvαCD20)-Fc-MBM-1 was about 65%.

[0272] Embodiment 18

[0273] Preparation of recombinant double-chain (scFvαCA19-9)-Fc-MBM X 2 DOTA

[0274] In this example, two DOTA bundles were coupled to the recombinant double-stranded (scFvαCA19-9)-Fc-MBM-1 or -MBM-3 of Example 9 using the method described in the above examples. The results of SDS-PAGE analysis showed that the coupling yields of the DOTA bundles and the recombinant double-stranded (scFvαCA19-9)-Fc-MBM-1 and -MBM-3 were approximately 65% ​​and 70%, respectively (data not shown).

[0275] Embodiment 19

[0276] Stabilization of the dual-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle

[0277] The ring-opening reaction was performed using the following method to make the double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle more stable.

[0278] The buffer of the molecular construct reaction product prepared in Example 14 was replaced with Tris buffer (100 mM Tris, pH 9.0, 100 mM L-arginine, and 100 mM sodium chloride) using a NAP-10 Sephadex G-25 column (GE Healthcare). The resulting solution was then heated to 37° C. for 5 hours. After the solution cooled, the buffer was replaced with 50 mM Bis-Tris buffer, pH 5.5 by centrifugation. The final sample was centrifuged to obtain approximately 1 to 3 mg / mL protein.

[0279] During purification, the stabilized product was adjusted to pH 5.5 and then added to a pre-equilibrated (50 mM Bis-Tris buffer, pH 5.5) anion exchange column Hi-TrapTM Q HP (GE Healthcare). The stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle was treated by stepwise elution, using the following conditions: 250 mM NaCl, 15 minutes, and a linear gradient of 250 mM to 324 mM NaCl, at a flow rate of 1.0 ml / min, for 50 minutes.

[0280] The stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle was then separated from uncoupled double-chain fusion proteins, double-chain fusion proteins coupled to three or four DOTA bundles, and aggregates using an anion exchange column Q HP. The purified product, double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle, was concentrated and the buffer was replaced with Tris buffer (50 mM Tris buffer, pH 7.0 and 290 mM NaCl).

[0281] Fig. 20 The FPLCQ HP elution spectrum of the stable double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle on anion exchange column. Fig. 20 As shown, the peak of the elution of the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X2 DOTA bundle was observed at 69.91 minutes. Fig.21 The results of SDS-PAGE analysis of different fractions collected from anion exchange column Q HP are shown. Electrophoresis bars A, B, C, and D correspond to uncoupled molecular constructs, molecular constructs coupled with one DOTA bundle, molecular constructs coupled with two DOTA bundles stabilized in the stock solution, and molecular constructs coupled with two DOTA bundles stabilized in the stock solution before loading into the column, respectively.

[0282] Depend on Fig.21 The pure product, ie, the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle, was collected from fractions #53, #54 and #55.

[0283] Embodiment 20

[0284] Stabilization of the double-chain (scFvαCD20)-Fc-MBM-1 X 2 DOTA bundle

[0285] Purification of the stabilized dual-chain (scFvαCD20)-Fc-MBM-1 X 2 DOTA bundle

[0286] A similar method as in Example 19 above was used to stabilize the double-chain (scFvαCD20)-Fc-MBM-1 X 2 DOTA bundle.

[0287] During purification, the stabilized product was adjusted to pH 5.1 and then added to a pre-equilibrated (50 mM acetic acid, pH 5.1) anion exchange column Hi-TrapTM Q HP (GE Healthcare). The stabilized double-chain (scFvαCD20)-Fc-MBM-1 X 2 DOTA bundle was treated by stepwise elution using 300 mM NaCl for 18 minutes and a linear gradient from 300 mM to 1,000 mM NaCl at a flow rate of 1.0 ml / min for 80 minutes.

[0288] The stabilized double-chain (scFvαCD20)-Fc-MBM-1 X 2 DOTA bundle was then separated from uncoupled double-chain fusion proteins, double-chain fusion proteins coupled to three or four DOTA bundles, and aggregates using an anion exchange column Q HP.

[0289] Fig. 22 The results of SDS-PAGE analysis of different fractions collected from the anion exchange column Q HP are shown. Electrophoresis bars A, B, and C correspond to the uncoupled molecular construct, the molecular construct coupled with one DOTA bundle, and the molecular construct coupled with two DOTA bundles stabilized before loading into the column, respectively.

[0290] Depend on Fig. 22 The pure product, ie, the stabilized double-chain (scFvαCD20)-Fc-MBM-1X 2 DOTA bundle, was collected from fractions #40 and #41.

[0291] Embodiment 21

[0292] MALDI-TOF analysis of stabilized dual-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle

[0293] The stabilized double-chain (scFvαCD19)-Fc-MBM-1 X2 DOTA bundle of Example 19 was analyzed using MALDI-TOF mass spectrometry. Fig.23 The results of MALDI-TOF analysis showed that the molecular weights of the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle samples were 114,435 and 57,306 Daltons, corresponding to m / z (z=1): [M+H] + and m / z(z=2):[M+2H] 2+ .

[0294] Embodiment 22

[0295] 89 Preparation of Y-labeled double-stranded (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle

[0296] In this example, a Y(NO3)3 solution was added to a solution containing the purified stable double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle from Example 19 at a molar ratio of 6:1 [Y 3+ ions: protein]; the reaction mixture was incubated at room temperature for 6 hours. Free Y was removed from the solution using a NAP-10 Sephadex G-25 column. 3+ ions. The stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2[ 89 Y] 3+ Chelated-DOTA bundles. Fig.24 The results of MALDI-TOF analysis showed that the molecular weight of the molecular construct presented here was 114,391 Daltons.

[0297] Embodiment 23

[0298] 175 Preparation of Lu-labeled double-stranded (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle

[0299] In this embodiment, LuCl 3 The solution was added to a solution containing purified stable double-chain (scFvαCD19)-Fc-MBM-1X 2 DOTA bundles at a molar ratio of 60:1 [Lu 3+ ions: protein]; the reaction mixture was then incubated at 45°C for 1.5 hours to obtain 175 Lu-DOTA-protein chelate. Free Lu was removed from the solution by spin filtration (Amicon centrifugal filter, 10 kDa). 3+ The stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 was analyzed by MALDI-TOF mass spectrometry. 175 Lu chelated-DOTA bundle. Fig.25 The results of MALDI-TOF analysis showed that the molecular weight of the molecular construct presented here was 114,928 Daltons.

[0300] Embodiment 24

[0301] 111 Preparation of ln-labeled double-stranded (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle

[0302] In preparation 111 When In-labeling fusion protein, 111 Aliquots of In in 50 mM HCl were transferred to test tubes, and 20 volumes of metal-free 0.1 M HEPES buffer were added to adjust the pH of the solution to 4.5. Then, a solution of double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle (30-50 μg) in 0.1 M HEPES buffer (pH 4.5) was added to a final protein concentration of 0.3-0.6 mg / mL. The resulting solution was gently mixed and incubated at 40-45°C for 60 minutes. Diethylenetriaminepentaacetic acid (DTPA) was added at 1,000 times the protein to capture free 111 In 3+ ions and quench the reaction. After incubation at 37°C for 30 minutes, 111 In-labeled product removal 111In-DTPA chelate was removed and the solvent was replaced with 0.9% saline by spin filtration (Amicon centrifugal filter, 10 kDa).

[0303] The radioactivity of appropriate aliquots of the sample is measured using a gamma counter to determine the amount of radioactivity collected. 111 Specific activity of In-labeled product.

[0304] Embodiment 25

[0305] 111 Analysis of Radioincorporation of In-labeled Dual-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA Beams

[0306] Radiochemical purity analysis was performed by instant thin-layer chromatography (iTLC). The radiolabeled product solution of Example 24 was diluted 1:10 or 1:20 with the original solvent; then, 1 μL of the sample was spotted on one end of a 1×10 cm TLC SG test strip. The test strip was developed using raw chromatography with 0.5 M sodium citrate (pH 4.5). The radioactivity was determined using a radio-TLC scanner. The radioactivity associated with the protein was expressed as a percentage of the total radioactivity. Fig.26 As shown, 111 The radiochemical purity of In-labeled double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle was higher than 98%.

[0307] Embodiment 26

[0308] 111 Stability test of In-labeled double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle in serum

[0309] Mouse serum was used at 37°C 111 In-labeled double-stranded (scFvαCD19)-Fc-MBM-1 X 2 DOTA beam was treated for 96 hours and its in vitro stability was also determined. 111 In-labeled molecular constructs were suspended in 0.2 M ammonium acetate (pH 5) and diluted 1:10 with mouse serum. 111 In-labeled molecular constructs were then incubated at 37°C for 96 hours. At selected time points (0, 12, 24, 48, and 96 hours), 111 In-labeled molecules were analyzed by radio-TLC as described in Example 25.

[0310] like Fig. 27 As shown, 111In-labeled double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundles could show ideal radioactivity after incubation in mouse serum at 37°C for 96 hours.

[0311] Embodiment 27

[0312] Position-specific coupling of recombinant double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundles

[0313] In order to confirm the cysteine ​​residues coupled to the DOTA tether in the double-chain (scFvαCD19)-Fc-MBM-1, the samples were decomposed and analyzed by LC-MS. Briefly, 5 μl of the sample from Example 11 (0.4 μg / mL) was diluted with a solution containing 15 μl of 25 mM tetraethylammonium tetrahydroborate (TEAB) and 2 μl of 200 mM TCEP and incubated at 55°C for 1 hour. After that, 2 μl of 375 mM iodine acetate (IAA) was added to the reaction mixture and incubated at room temperature for 30 minutes. After IAA alkylation, enzymes (trypsin and Glu-C) were added to the solution and reacted overnight at 37°C to allow the enzyme to decompose the sample.

[0314] Mass spectrometry data (data not shown) showed that the m / z value of the fragment in the MS spectrum corresponded to 4,530.99 Daltons, consistent with the estimated molecular weight of a molecular construct containing the amino acid sequence of SLSLSPGGGGACPGHA (amino acid residues 468-483 of SEQ ID NO: 13) and a DOTA tract.

[0315] Embodiment 28

[0316] Binding activity of stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle to human B lymphoma cell lines

[0317] The binding ability of two stabilized molecular constructs, (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle and (scFvαCD19)-Fc-MBM-3 X 2 DOTA bundle, to human CD19 on the human B lymphoma cell line Raji was analyzed. 6CD19-expressing Raji cells were incubated with 0.001 μg / ml of the molecular constructs in PBS in 1% BSA on ice for 30 minutes. Anti-CD19 antibody (RB4v1.2), (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundles and (scFvαCD19)-Fc-MBM-3 X 2 DOTA bundles were used as positive controls. Anti-HER2 antibody (trastuzumab) was used as a negative control. Cell staining was analyzed by FACS (FACSCanto II, BD Biosciences) with FITC-conjugated goat anti-human IgG.Fc (diluted 1:200 in PBS / BSA) (Caltag, Buckingham, UK) at 4°C in the dark for 20 minutes. Fig.28A and 28B The results of cell staining of two molecular constructs containing MBM-1 and MBM-3 on Raji cells expressing CD19 are shown, and the results indicate that both molecular constructs can substantially bind to Raji cells.

[0318] The binding ability of the above molecular constructs to human CD19 on the human B lymphoma cell line Ramos was analyzed. The analysis here was performed using a method similar to the cell binding analysis performed above for Raji cells. Ramos cell staining was analyzed using FACS (FACSCanto II, BD Biosciences) with FITC-complexed goat anti-human IgG.Fc, with anti-CD19 IgG as a positive control group. Anti-HER2 antibody (trastuzumab) was used as a negative control group. Fig.28C and 28D The results of cell staining of two molecular constructs containing MBM-1 and MBM-3 on Ramos cells expressing CD 19 are shown. Both molecular constructs can substantially bind to Ramos cells.

[0319] Embodiment 29

[0320] Stability of the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle

[0321] To stabilize the double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle, the molecular construct was placed in Tris buffer (100 mM Tris buffer, pH 7.3, 50 mM Bis-Tris buffer and 290 mM NaCl) containing glutathione or human serum albumin (HSA) and incubated at 37°C for 30 days.

[0322] As shown in Figure 28, the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundles can still show ideal stability after incubation with glutathione or human serum albumin at 37°C for 30 days. As shown in Figure 28, in both groups treated with glutathione and human serum albumin, about 90% of the full-length molecular constructs were still retained in the solution without reverse Michael addition products. Electrophoresis bars U and C correspond to the uncoupled molecular constructs and the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundles stored at 4°C, respectively, as controls.

[0323] Embodiment 30

[0324] Examination of the reverse Michael addition product of the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle

[0325] To further confirm the stability of the double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle, the stabilized molecular construct was incubated with glutathione or HSA, followed by western blotting analysis.

[0326] Briefly, when the stabilized samples were subjected to western blotting, the samples were separated by 8% SDS-PAGE gel and transferred to poly(vinylidene fluoride, PVDF) membrane (Millipore). The blots on the membrane were blocked with PBS containing 5% BSA and 0.05% Tween 20 at room temperature for 1 hour. After washing three times with phosphate buffered saline-Tween20 (PBST) containing PBS and 0.05% Tween-20, the blots were then incubated with goat anti-human IgG.Fc antibody (Millipore) complexed with horseradish peroxidase (HRP). Afterwards, the membrane was washed three times with PBST, and the immunoreactive bands were detected using ECLTM Western Blot Detection Reagent (Millipore) and exposed to Fujifilm (Tokyo, Japan).

[0327] Fig.30 The results of Western blot analysis of the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle are shown in Figure 2. Fig.29As shown, the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle can still show ideal stability after incubation with glutathione or human serum albumin at 37°C for 30 days, compared with the stabilized molecular construct stored at 4°C (electrophoresis bar C). Electrophoresis bar U is the uncoupled molecular construct as a control.

[0328] Embodiment 31

[0329] Half-life of stabilized dual-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle

[0330] The half-life of the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle was determined after intravenous injection into mice. The (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle in the serum was analyzed by ELISA. This experiment used 8 to 10 week old BALB / c mice purchased from BioLasco (Taiwan, China). The mice were divided into groups of 6 and injected intravenously with about 200 μL of 3.33 μM protein.

[0331] Fig.31 The pharmacokinetic profiles of anti-CD19 antibody (RB4v1.2) and double-chain (scFvαCD19)-Fc-MBM-1 fusion protein are shown. It can be seen from the figure that the half-lives of anti-CD19 antibody (RB4v1.2), (scFvαCD19)-Fc-MBM-1 fusion protein of Example 3, the molecular construct (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle of Example 18, and the stabilized molecular construct (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle of Example 19 are about 129, 179.6, 153.6, and 193.5 hours, respectively. In summary, the stabilization treatment can prolong the half-life of the stabilized molecular construct.

[0332] Embodiment 32

[0333] Effect of stabilized dual-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle on targeting of CD19-expressing xenograft tumors

[0334] In this example, an in vivo imaging system (IVIS) was used to determine the effect of the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle on CD19-expressing tumors in a mouse xenograft model. Before IVIS development, the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle of Example 19 and the anti-CD19 antibody (RB4v1.2) were labeled with the Dylight 680 antibody labeling kit (ThermoScientific) according to the manufacturer's instructions.

[0335] This experiment used 8- to 10-week-old NOD-SCID (NOD.CB17-Prkdcscid / JNarl) purchased from the Laboratory Animal Factory of the Institute of Cell and Organism Biology, Academia Sinica (Taiwan, China). Two weeks before treatment, 1×10 7 B-cell lymphoma Raji cells were injected intraperitoneally into each mouse. The mice were divided into groups of three mice each and injected intravenously with approximately 200 μL of 6.65 μM labeled molecules. At different time points, the mice were anesthetized with isoflurane in oxygen and placed in a supine position in an IVIS Spectrum In Vivo Imaging System (PerkinElmer). Fluorescent images were captured using Living Image Software V3.2 at Ex / Em=675 / 720. After the IVIS Spectrumimager acquired the images at the specified time, they were analyzed using Living Image Software.

[0336] Fluorescent images of NOD-SCID mice were acquired and analyzed at 0, 24, 48, and 72 hours after injection of Dylight 680-complex protein. Fig.32 The distribution of fluorescently labeled molecules in the mouse model is shown. NOD-SCID mice were injected intravenously with anti-CD19 antibody (RB4v1.2) (1 and 2) and stabilized with two-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundles (3 and 4).

[0337] like Fig.32 As shown, at 24, 48 and 72 hours after intravenous injection, the amount of stabilized two-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle and anti-CD19 antibody (RB4v1.2) entering the tumor on the right is much higher than that entering the normal organ on the left. Therefore, the stabilized molecular constructs showed an ideal targeting effect on CD19-expressing tumors in mouse xenograft models.

[0338] Embodiment 33

[0339] Biodistribution of the stabilized dual-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle in mice bearing CD19-expressing xenograft tumors

[0340] The method described in Example 32 was used with minor modifications to evaluate the biodistribution of the stabilized (scFvαCD19)-Fc-MBM-1 X 2DOTA bundle in a xenograft mouse model.

[0341] Briefly, 1×107 B-cell lymphoma Raji cells were injected subcutaneously per mouse 2 to 3 weeks prior to treatment. The mice were divided into groups of three mice each and injected intravenously with approximately 200 μL of 6.65 μM labeled molecule.

[0342] Tissue ELISA was performed 7 days after injection of stabilized two-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundles and anti-CD19 antibody to analyze the biodistribution of NOD-SCID mice. Briefly, animals were sacrificed on day 7 after injection. Cardiac blood was bled and tissue samples of 11 organs were collected. Tissue samples were homogenized with a homogenizer and further analyzed by ELISA for the concentration of the injected molecules.

[0343] Fig.33 The distribution of the stabilized double-chain (scFvαCD19)-Fc-MBM-1 X 2 DOTA bundle (TE-1122) in the mouse model. The Y-axis in the biodistribution graph represents the ratio of tissue to blood. The results here also show that the stabilized molecular construct is able to target CD19-expressing tumors in the mouse xenograft model.

[0344] Embodiment 34

[0345] Synthesis of Aib-GLP-1 agonist with terminal cysteine ​​residue

[0346] In this example, a glucagon-like peptide 1 (GLP-1) agonist (SEQ ID NO: 37) containing a free cysteine ​​at the C-terminus and carrying an ε-aminoisobutyric acid (Aib) substituent was prepared. Fig.34The schematic structure of the present molecular construct is shown in Figure 2. Similar to semaglutide, its second amino acid residue is substituted with an Aib (or U) residue, making it more resistant to degradation caused by dipeptidyl peptidase IV (DPP 4); however, in the present molecular construct, a flexible conjugate with a length of 15 amino acid residues (i.e., amino acid residues 31 to 45 of SEQ ID NO: 37) is added before the last glycine residue of semaglutide (i.e., amino acid residue 46 of SEQ ID NO: 37), and a terminal cysteine ​​residue is added at the C-terminus.

[0347] The inventors of the present invention designed the structure of Aib-GLP-1 agonist-Cys and commissioned Shanghai WuXi AppTech Co., Ltd. (Shanghai, China) to synthesize it.

[0348] The purified sample of Aib-GLP-1 agonist-Cys was analyzed by reverse phase analytical HPLC on a Supelco C18 column (250 mm×4.6 mm; 5 μm), using acetonitrile and 0.1% trifluoroacetic acid as the mobile phase, a linear gradient of acetonitrile from 0% to 100% in 30 minutes, a flow rate of 1.0 ml / min and a column temperature of 25°C.

[0349] ESI-MS mass spectrometry was used to identify the Aib-GLP-1 agonist-Cys product. The Aib-GLP-1 agonist-Cys product sample showed a strong molecular ion at 1,483.4, corresponding to [M+H] + , which means that the actual molecular weight of the Aib-GLP-1 agonist-Cys agonist proposed here is 1,482.4 Daltons.

[0350] Embodiment 35

[0351] Synthesis of somatostatin analogs with a terminal cysteine ​​residue

[0352] In this example, a somatostatin analogue with a free cysteine ​​at the N-terminus was prepared; the amino acid sequence of this Cys-somatostatin polypeptide molecular construct is shown in SEQ ID NO:38. Fig.35The schematic structure of the present molecular construct is shown below. The present molecular construct has 14 amino acid residues, in which an N-terminal cysteine ​​residue is added, followed by a flexible linker of 5 amino acid residues and a somatostatin polypeptide sequence. Similar to the original somatostatin polypeptide, the seventh amino acid residue (Phe) and the tenth amino acid residue (Trp) of the Cys-somatostatin polypeptide molecular construct proposed here are D-type, and a disulfide bridge is formed between the 8th and 13th cysteine ​​residues, and the C-terminal threonine residue is threonol. In addition, the N-terminus of the Cys-somatostatin polypeptide molecular construct is modified by an acetyl group.

[0353] The inventors of the present invention designed the structure of the Cys-somatin polypeptide molecular construct proposed herein and commissioned Ontores Biotechnologies Co., Ltd. (Hangzhou, China) to synthesize it using a standard solid-state synthesis method. The purity of the Cys-somatin polypeptide product was higher than 95%.

[0354] Cys-somatin peptide products were analyzed using MALDI-TOF mass spectrometry. Mass spectrometry analysis was performed at the mass spectrometry core facility of the Institute of Molecular Biology, Academia Sinica (IMB, Taiwan, China). The equipment used was a Bruker Autoflex III MALDI-TOF / TOF mass spectrometer (purchased from Bruker Daltonics, Bremen, Germany). Fig.36 The results of MALDI-TOF mass spectrometry analysis showed that the molecular weight of the molecular construct proposed here was 1,493.587 Daltons.

[0355] Embodiment 36

[0356] Synthesis of PSMA ligands with cysteine ​​residues

[0357] In this example, a PSMA ligand with a free cysteine ​​residue was prepared. The structure of this molecular construct is as follows: Fig.37 shown.

[0358] The inventors of the present invention designed the structure of the Cys-PSMA ligand molecular construct proposed herein and commissioned Shanghai WuXi AppTech Co., Ltd. (Shanghai, China) to synthesize it. The purity of the Cys-PSMA ligand product was higher than 95.0%.

[0359] ESI-MS mass spectrometry was used to identify the Cys-PSMA ligand. Fig.38 The ESI-MS mass spectrometry results showed that the molecular construct proposed here exhibited a strong molecular ion at 522.4, corresponding to [M+H] +, which means that the true molecular weight of the Cys-PSMA ligand is 521.4 Daltons.

[0360] Embodiment 37

[0361] Synthesis of Calcitonin-MBM-1

[0362] In this example, a molecular construct of calcitonin with a metal binding domain at the C-terminus was prepared; the amino acid sequence of this calcitonin-MBM-1 molecular construct is shown in SEQ ID NO:39. Fig.39 The schematic structure of the present molecular construct is shown in Figure 2. Similar to calcitonin, a disulfide bridge is formed between the 7th cysteine ​​residue and the calcitonin proline residue; however, in the present molecular construct, a flexible conjugate of 8 amino acid residues (amino acid residues 33-40 of SEQ ID NO: 39) is introduced after the last proline residue of calcitonin (i.e., the 32nd amino acid residue of SEQ ID NO: 39), and the MBM-1 domain (ACPGHA, SEQ ID NO: 7) is added to the C-terminus of the flexible conjugate.

[0363] The inventors of the present invention designed the structure of the calcitonin-MBM-1 molecular construct proposed herein and commissioned Shanghai WuXi AppTech Co., Ltd. (Shanghai, China) to synthesize it. The purity of the Cys-PSMA ligand product was higher than 95.0%.

[0364] Embodiment 38

[0365] Synthesis of Teriparatide-MBM-1

[0366] In this example, a molecular construct of teriparatide with a metal binding domain at the C-terminus was prepared; the amino acid sequence of this teriparatide-MBM-1 molecular construct is shown in SEQ ID NO: 40. Teriparatide is a parathyroid (PTH) hormone, which is composed of the active site of the first 34 amino acids of the hormone. It can be used to treat certain types of osteoporosis. In the teriparatide-MBM-1 molecular construct, a flexible conjugate with a length of 15 amino acid residues (amino acid residues 35-49 of SEQ ID NO: 40) is introduced after the last phenylalanine residue of teriparatide (i.e., the 34th amino acid residue of SEQ ID NO: 40), and the MBM-1 domain (ACPGHA, SEQ ID NO: 7) is added to the C-terminus of the flexible conjugate.

[0367] The inventors of the present invention designed the structure of the teriparatide-MBM-1 molecular construct proposed herein and commissioned Shanghai WuXi AppTech Co., Ltd. (Shanghai, China) to synthesize it. The purity of the Cys-PSMA ligand product was higher than 95.0%.

[0368] Embodiment 39

[0369] Synthesis of Leuprorelin-MBM-3

[0370] In this example, a molecular construct of leuprolide with a metal binding domain at the C-terminus was prepared; the amino acid sequence of this leuprolide-MBM-3 molecular construct is shown in SEQ ID NO: 41. Leuprolide (also known as leuprolide) is a gonadotropin-releasing hormone (GnRH) analog that can be used as an agonist of various GnRH receptors and can be used to treat prostate cancer and breast cancer. Commercially available leuprolide is an oligopeptide with 9 amino acid residues. In the leuprolide-MBM-3 molecular construct proposed here, a flexible conjugate with a length of 8 amino acid residues (amino acid residues 10-17 of SEQ ID NO: 41) is introduced after the last proline residue of leuprolide (i.e., the 9th amino acid residue of SEQ ID NO: 41), and the MBM-3 domain (GCGGHA, SEQ ID NO: 6) is added to the C-terminus of the flexible conjugate.

[0371] The inventors of the present invention designed the structure of the leuprorelin-MBM-3 molecular construct proposed herein and commissioned Shanghai WuXi AppTech Co., Ltd. (Shanghai, China) to synthesize it. ESI-MS mass spectrometry analysis was used to identify the leuprorelin-MBM-3 molecular construct proposed herein. The results of ESI-MS mass spectrometry analysis showed that the molecular construct proposed herein exhibited a strong molecular ion at 1,091.97, corresponding to [M+2H] 2+ , which means the true molecular weight of the leuprolide-MBM-3 molecular construct is 2,181.35 Daltons.

[0372] Embodiment 40

[0373] Synthesis of the lenalidomide bundle

[0374] In this embodiment, two drug-loaded bundles were designed, which used a maleimide-containing polypeptide with three lysine residues as the central core, and three lenalidomide molecules were coupled to the central core. The lenalidomide bundles proposed herein were synthesized using a comprehensive method, wherein the central core was synthesized using the Fmoc standard solid-state synthesis method, followed by a liquid-state synthesis to connect the lenalidomide molecules modified with the linker to the side chains of the lysine residues of the central core. The molecular constructs were synthesized by Shanghai WuXi AppTech Co., Ltd. (Shanghai, China).

[0375] Fig.40 A Mal-peptide 3-lenalidomide tract is shown, wherein the sequence of the core is EGEGEAGGKGAGKGAGKG (SEQ ID NO: 42), wherein the first amino acid residue is modified with maleimide vinyl. On the other hand, the lenalidomide molecule is modified with a para-amino benzyl carbamate (PABC)-alanine-valine-PEG linker before coupling it to the core. The lenalidomide molecule is linked to the ε-amino group of the lysine residue of the core via the free end of the linker.

[0376] ESI-MS mass spectrometry was used to identify the Mal-peptide 3-lenalidomide bundle. Fig.41 The ESI-MS mass spectrometry results showed that the proposed drug-loaded beam exhibited a strong molecular ion at 1,321.9, corresponding to [M+3H] 3+ , which means that the true molecular weight of the Mal-peptide 3-lenalidomide bundle is 3,962.02 Daltons.

[0377] Fig.42 A Mal-peptide 4-lenalidomide tract is shown, wherein the sequence of the core is EDEDEAGGKGAGKGAGKG (SEQ ID NO: 43), wherein the first amino acid residue is modified with maleimide vinyl. On the other hand, the lenalidomide molecule is modified with the above-mentioned linker before coupling it to the core, and is linked to the ε-amino group of the lysine residue of the core through the free end of the linker.

[0378] ESI-MS mass spectrometry was used to identify the Mal-peptide 4-lenalidomide bundle. The ESI-MS mass spectrometry results showed that the proposed drug-loaded bundle exhibited a strong molecular ion at 1,379.2, corresponding to [M+3H] 3+ , which means that the true molecular weight of the Mal-peptide 4-lenalidomide bundle is 4,135.15 Daltons.

[0379] Embodiment 41

[0380] Synthesis of Mal-fatty acid bundles

[0381] In this example, a molecular construct consisting of a Mal-polypeptide 5 central core and a stearoyldiacid chain and a palmitic acid chain was prepared.

[0382] Fig.43 The structure of the Mal-peptide 5-fatty acid bundle is shown, and the sequence of the central core is maleimide ethyl EGEGE-X 1 -KX 2 -K-OMe (SEQ ID NO: 44), wherein the first amino acid residue is modified with maleimide vinyl, the last lysine residue is modified with methoxy (-OMe), and X 1 With X 2 They are all PEGylated amino acids with 4 EG repeating units. One stearoyl dicarboxylic acid chain and one palmitic acid chain are respectively linked to the CO 2 The amide bond formed between the H group and the amino group of the K residue is connected to the K residue of the polypeptide core. The inventors of the present invention designed the structure of the Mal-peptide 5-fatty acid bundle proposed herein and commissioned Shanghai WuXi AppTech Co., Ltd. (Shanghai, China) to synthesize it. The purity of the Mal-peptide 5-fatty acid bundle product is higher than 97.0%.

[0383] ESI-MS mass spectrometry was used to identify the synthesized fatty acid bundles. Fig.44 The ESI-MS mass spectrometry results showed that the proposed drug-loaded beam exhibited a strong molecular ion at 1,143.6, corresponding to [M+2H] 2+ , which means that the true molecular weight of the Mal-polypeptide 5-fatty acid bundle is 2,285.66 Daltons.

[0384] Embodiment 42

[0385] Synthesis of 3-DOTA arm-joining units

[0386] In this example, a 3-DOTA arm junction unit was prepared to carry three polypeptides. Fig.45 The structure of the 3-arm conjugate is shown in FIG. 4. Specifically, the conjugate unit comprises a central core having a sequence of acetyl-KGAGGKGAGGKG (SEQ ID NO: 45, polypeptide core 6), wherein the first lysine residue is modified with an acetyl group. The conjugate unit also comprises three connecting arms having a sequence of maleimideethyl EGEGEAGKGAG (SEQ ID NO: 46), wherein the first glutamic acid residue is modified with maleimidevinyl, and the lysine residue is modified with a DOTA molecule.

[0387] The inventors of the present invention designed the structure of the 3-DOTA arm-joining unit proposed herein and commissioned Shanghai WuXi AppTech Co., Ltd. (Shanghai, China) to synthesize it. The synthesized 3-DOTA arm-joining unit was identified by ESI-MS mass spectrometry analysis. Fig.46 The ESI-MS mass spectrometry results showed that the proposed drug-loaded beam exhibited a strong molecular ion at 1,357.8, corresponding to [M+4H] 4+ , which represents a true molecular weight of 5,427.2 Daltons for the 3-DOTA arm-joining unit.

[0388] Embodiment 43

[0389] Construction, expression and purification of recombinant MBM-1-IL-2

[0390] In this example, a complex protein as shown in SEQ ID NO: 47 was constructed, expressed and purified using methods similar to those in the above examples. Specifically, the MBM-1-IL-2 molecular construct presented here has an MBM-1 domain followed by a short flexible linker (SEQ ID NO: 9) and an IL-2 sequence.

[0391] The culture supernatant was collected and purified using an anion exchange column to purify the recombinant fusion protein expressed in the culture medium. Before purification, the recombinant MBM-1-IL-2 fusion protein was adjusted to pH 8.5. Afterwards, the protein was added to a pre-equilibrated (50 mM Bis-Tris buffer, pH 8.5) Q sepharose anion exchange column (GE Healthcare). The MBM-1-IL-2 fusion protein was treated with a 3-stage extraction method, which was 200 mM, 500 mM and 1 M NaCl in 4 M urea solution, pH 8.5.

[0392] The eluted product was analyzed by 10% SDS-PAGE. Fig.47 The main band of MBM-1-IL-2 fusion protein is located at about 16 kDa, which is consistent with the expected size (as shown by the arrow).

[0393] Embodiment 44

[0394] Synthesis of double-chain (scFvαCD38)-Fc-MBM-1 X 2 lenalidomide bundle

[0395] In this example, the (scFvαCD38)-Fc-MBM-1 fusion protein of Example 10 and the Mal-peptide 4-lenalidomide tether of Example 40 were coupled, and the resulting molecular construct had a double-chain (scFvαCD38)-Fc-MBM-1 fusion protein and two lenalidomide tethers were coupled to the cysteine ​​residues of the respective metal binding domains of the fusion protein. Briefly, the purified (scFvαCD38)-Fc-MBM-1 fusion protein was placed in sodium succinate buffer (30 mM sodium succinate, pH 5.3, 0.02% Tween 20 and 100 mM sucrose) and incubated with 45 μM TCEP for 30 minutes with gentle shaking at room temperature to reduce it. After the reduction reaction, the protein was dialyzed against 10 mM sodium succinate buffer (pH 5.3 containing 0.02% Tween 20 and 100 mM sucrose) containing 60 μM Zn(II) ions to remove excess TCEP. Afterwards, the reduced protein sample was treated with 15 μM Mal-peptide 4-lenalidomide bundle and then incubated at room temperature for 1 hour. Unreacted lenalidomide bundle was removed using a desalting column, and the product was analyzed using SDS-PAGE.

[0396] Fig.48 The SDS-PAGE analysis results of the molecular construct proposed herein show that the molecular weight of the molecular construct is about 120 kDa (as indicated by arrow #1 in electrophoresis strip 2), which is slightly smaller than the expected size. Electrophoresis strip 3 is a sample of the uncoupled fusion protein (as indicated by arrow #2). Fig.48 As shown, the coupling yield of the double-chain (scFvαCD38)-Fc-MBM-1 and the lenalidomide tract was approximately 85%.

[0397] Embodiment 45

[0398] Synthesis of X-fatty acid bundle of somatostatin polypeptide

[0399] In this example, the Mal-polypeptide 5-fatty acid bundle of Example 41 and the Cys-somatin polypeptide of Example 35 were coupled using a method similar to that of the above examples, so that the maleimide ethyl group of the Mal-polypeptide 5-fatty acid bundle and the SH group of the terminal cysteine ​​residue of the Cys-somatin polypeptide were coupled, thereby obtaining a molecular construct of the somatin polypeptide X fatty acid bundle (see, Fig.49 ).

[0400] Embodiment 46

[0401] Synthesis of the X-fatty acid bundle of Aib-GLP-1 agonist

[0402] In this example, the Mal-polypeptide 5-fatty acid bundle of Example 41 and the Aib-GLP-1 agonist-Cys of Example 34 were coupled using a method similar to that of the above examples, so that the maleimide ethyl group of the Mal-polypeptide 5-fatty acid bundle and the SH group of the terminal cysteine ​​residue of the Aib-GLP-1 agonist-Cys were coupled, thereby obtaining a molecular construct of the Aib-GLP-1 agonist X fatty acid bundle (see, Fig.50A ).

[0403] Embodiment 47

[0404] Synthesis of Teriparatide-MBM-1 X fatty acid bundle

[0405] In this example, the Mal-polypeptide 5-fatty acid bundle of Example 41 and the teriparatide-MBM-1 of Example 38 were coupled using a method similar to that of the above examples to obtain a molecular construct of teriparatide-MBM-1 X fatty acid bundle (see, Fig.50B ).

[0406] Embodiment 48

[0407] Synthesis of Leuprorelin-MBM-3X fatty acid bundle

[0408] In this example, the Mal-polypeptide 5-fatty acid bundle of Example 41 and the leuprorelin-MBM-3 of Example 39 were coupled using a method similar to that of the above examples to obtain a molecular construct of the leuprorelin-MBM-3X fatty acid bundle (see, Fig.51A ). The synthesized leuprorelin-MBM-3X fatty acid bundle was identified by MALDI-TOF mass spectrometry. The results are as follows Fig.51B As shown, the molecular weight of the molecular construct is 4,466.019 Daltons. The molecular weight of 2,181.038 Daltons shows that in this reaction, under the condition of [leuprolide-MBM-3:Mal-peptide 5-fatty acid] molar ratio of 1.5:1, leuprolide-MBM-3 is in excess.

[0409] Embodiment 49

[0410] Synthesis of 3-DOTA arm-joining unit x 3 PSMA ligand

[0411] In this example, the 3-DOTA arm-binding unit of Example 42 and three Cys-PSMA ligands from Example 36 were coupled using a method similar to the above example to obtain a molecular construct of 3-DOTA arm-binding unit x 3 PSMA ligands (see, Fig.52A). The synthesized 3-DOTA arm-joining unit X 3PSMA ligand was identified by ESI-MS mass spectrometry analysis, and the results are as follows: Fig.52B As shown, the molecular construct proposed here exhibits a strong molecular ion at 1,79, corresponding to [M+4H] 4+ , which represents the true molecular weight of the 3-DOTA arm-joining unit X 3 PSMA ligand to be 6,992.18 Daltons.

[0412] Embodiment 50

[0413] Purification of the stabilized double-chain (scFvαCA19-9)-Fc-MBM-1 X 2 DOTA bundle

[0414] The recombinant double-chain (scFvαCA19-9)-Fc-MBM-1 X 2 DOTA bundle was stabilized using the method described in the above examples.

[0415] The double-stranded fusion coupled with two DOTA bundles of the above example was adjusted to pH 5.0, and then added to a pre-equilibrated (0.1 mM EDTA, 50 mM Bis-Tris, pH 5.0) anion exchange column Qsepharose (GE Healthcare). The sample was processed using a 3-step elution method; the first elution used 320 mM NaCl for 70 minutes, followed by a second elution using 330 mM for 100 minutes, and a final elution using 1,000 mM NaCl for 50 minutes, with a flow rate of 1.0 ml / min.

[0416] The double-stranded (scFvαCA19-9)-Fc-MBM-1 X 2DOTA bundle was then separated from the uncoupled double-stranded (scFvαCA19-9)-Fc-MBM-1 fusion protein, the double-stranded (scFvαCA19-9)-Fc-MBM-1 fusion protein coupled with three or four DOTA bundles, and the aggregates using an anion exchange column Q sepharose.

[0417] The purified product, double-chain (scFvαCA19-9)-Fc-MBM-1 X 2 DOTA bundle, was collected. Fig.53 The electrophoretic strip 1 and the electrophoretic strip 2 shown correspond to an uncoupled molecular construct and a molecular construct coupled with two DOTA bundles, respectively.

[0418] Embodiment 51

[0419] Purification of the stabilized dual-chain (scFvαCD38)-Fc-MBM-1 X 2 lenalidomide tract

[0420] The double-chain (scFvαCD38)-Fc-MBM-1×2 lenalidomide bundle molecular construct of Example 44 was stabilized in the manner described in the above Examples.

[0421] The stabilized double-chain (scFvαCD38)-Fc-MBM-1 X 2 lenalidomide bundle molecular construct was adjusted to pH 7.0 and then added to the pre-equilibrated (50mM Na2HPO4, pH 7.0, 1M NaCl) hydrophobic interaction column (HIP) Phenyl HP (GE Healthcare). The stabilized molecular construct was eluted using a linear gradient with the following conditions: 1,000mM to 0mM NaCl, flow rate 1.0ml / min, for 80 minutes.

[0422] The sample collected from the aforementioned HIC purification column was added to a size exclusion chromatography column ENrichTM SEC650 (Bio-Rad) to separate the stabilized molecular construct and aggregates, and the purified product was collected. Fig.54 It is the result of 10% non-reducing SDS-PAGE analysis, wherein electrophoresis strip 1 and electrophoresis strip 2 correspond to the uncoupled molecular construct and the molecular construct coupled with two lenalidomide bundles, respectively.

[0423] The purified stabilized double-chain (scFvαCD38)-Fc-MBM-1X 2 lenalidomide bundle molecular construct was further analyzed using MALDI-TOF mass spectrometry. Fig.55 The mass spectrometry results shown below show that the molecular weights of the samples are 58,382 and 116,705 Daltons, corresponding to m / z (z=1): [M+H] + and m / z(z=2):[M+2H] 2+ .

[0424] Fig.55 The upper part shows the mass spectrometry analysis results of the double-chain (scFvαCD38)-Fc-MBM-1 as a control, with molecular weights of 54,300 and 108,537 Daltons, corresponding to m / z (z=1): [M+H] + and m / z(z=2):[M+2H] 2+ .

[0425] Embodiment 52

[0426] Half-life of lenalidomide tethered by stabilized dual-chain (scFvαCD38)-Fc-MBM-1 X 2 in NOD-SCID mice

[0427] The half-life was determined after intravenous injection of a stabilized double-chain (scFvαCD38)-Fc-MBM-1 X 2 lenalidomide bundle into mice. ELISA was used to analyze the molecular constructs in serum. This experiment used 8 to 10 week old NOD-SCID mice purchased from BipLasco (Taiwan, China). The mice were divided into groups of 3 and injected intravenously with approximately 100 μL of 7.6 μM protein.

[0428] The analysis results showed that the parental anti-CD38 hIgG1.Fc antibody ( Fig.56A ) and double-chain (scFvαCD38)-Fc-MBM-1 X 2 lenalidomide bundle ( Fig.56B The half-life of lenalidomide molecule is about 13.1 hours and 23.9 hours respectively. The results calculated by non-compartmental pharmacokinetic model showed that the half-life of the double-chain (scFvαCD38)-Fc-MBM-1 X 2 lenalidomide bundle proposed here is longer than that of traditional anti-CD38 antibodies.

[0429] Embodiment 53

[0430] Cytotoxicity of purified double-chain (scFvαCD38)-Fc-MBM-1 X 2 lenalidomide bundle on H929 and CD38-positive U266 cells

[0431] H929 cells (5×10 3 / well) was added to the wells of a 96-well plate, and the culture medium used was RPMI1640 containing 10% fetal bovine serum. After 2 hours, 20 μM of purified double-chain (scFvαCD38)-Fc-MBM-1 (without lenalidomide bundle) or double-chain (scFvαCD38)-Fc-MBM-1 X 2 lenalidomide bundle was added to each well after 2-fold serial dilution. After 2 hours of incubation, the culture medium was removed and replaced with fresh culture medium by centrifugation at 400g for 5 minutes, and the cells were then incubated for another 120 hours (5 days) and 168 hours (7 days). Then, the cell viability was analyzed using the alamarBlue cell viability reagent kit (Invitrogen) according to the manufacturer's instructions.

[0432] The cytotoxicity of purified double-chain (scFvαCD38)-Fc-MBM-1 with or without two lenalidomide tracts on CD38-positive U266 cells was determined in a similar manner as above for H929 cells.

[0433] Fig.57AThe survival rate of H929 cells in four treatment groups is shown. After 5 days of treatment with 20μM double-chain (scFvαCD38)-Fc-MBM-1 X 2 lenalidomide beam (labeled as scFv-Fc-len), about 80% of H929 cells were lysed. The double-chain (scFvαCD38)-Fc-MBM-1 (labeled as scFv-Fc) as a negative control had no cytotoxic effect.

[0434] Fig.57B The survival rate of CD38-positive U266 cells in four treatment groups is shown. After 5 days of treatment with 20 μM of double-chain (scFvαCD38)-Fc-MBM-1 X 2 lenalidomide bundle (labeled as scFv-Fc-len), about 80% of CD38-positive U266 cells were lysed.

[0435] Fig.57C The figure shows the survival rate of CD38-negative U266 cells in the four treatment groups. No matter what the molar concentration of the double-chain (scFvαCD38)-Fc-MBM-1 X 2 lenalidomide bundle (labeled as scFv-Fc-len) could not induce cell lysis of CD38-negative U266 cells.

[0436] In summary, Figures 57A to 57C The results showed that the double-chain (scFvαCD38)-Fc-MBM-1 X 2 lenalidomide bundle had a strong targeting effect.

[0437] Embodiment 54

[0438] Purified double-chain (scFvαCD38)-Fc-MBM-1 X 2 lenalidomide bundles induce antibody-mediated cytotoxicity (ADCC) against CD38-expressing H929 and U266 cells

[0439] In this example, in vitro analysis was performed to investigate the effect of antibody-dependent cell-mediated cytotoxicity (ADCC) of dual-chain (scFvαCD38)-Fc-MBM-1×2 lenalidomide-bound antibodies on the cytolysis of CD38-expressing H929 cells and CD38-positive U266 cells.

[0440] Human peripheral blood mononuclear cells (PBMCs) were obtained from donors to analyze ADCC function. H929 cells or CD38-positive U266 cells were incubated with double-chain (scFvαCD38)-Fc-MBM-1X 2 lenalidomide bundles at a final concentration of 200, 40, 8, 1.6, 0.32, or 0.064 nM, and then mixed with human PBMCs at an E:T ratio of 25 and incubated at 37°C for 5 hours. Parental anti-CD38 mAb was used as a positive control. Cell lysis was analyzed using the LDH cytotoxicity assay kit (Enzo Life Sciences).

[0441] The data presented here indicate that purified dual-chain (scFvαCD38)-Fc-MBM-1 X 2 lenalidomide tracts (labeled as scFv-Fc-len) can recruit effector cells in a manner similar to the parental anti-CD38 monoclonal antibody to induce cytolytic activity ( Fig.58A The parental anti-CD38 antibody (labeled as IgG) was used as a positive control, and an isotype control antibody (labeled as control IgG) was also used.

[0442] like Fig.58B As described above, the purified double-chain (scFvαCD38)-Fc-MBM-1×2 lenalidomide bundle (labeled as scFv-Fc-len) can exhibit cytolytic activity similar to that of the parent substance in CD38-positive U266 cells. It should be understood that the description of the above embodiment is only for illustration, and various modifications can be made to it by technicians in the technical field to which the present invention belongs. The above description, examples and data fully illustrate the structure and use of the exemplary embodiments of the present invention. Although the specific embodiments of the present invention are disclosed in the above embodiments, they are not used to limit the present invention. Technicians in the technical field to which the present invention belongs can make various changes and modifications to it without departing from the principles and spirit of the present invention. Sequence Listing <110> Immune Power Co., Ltd. <120> Composite polypeptide with metal binding region and molecular construct thereof <130> P3187-PCT <150> US62 / 823,626 <151> 2019-03-25 <160> 47 <170> BiSSAP 1.3.6 <210> 1 <211> 5 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <220> <221> Variants <222> 2 <223> Xaa is glycine or proline <220> <221> Variants <222> 3 <223> Xaa is glycine or alanine <400> 1 Cys Xaa Xaa His Ala 1 5 <210> 2 <211> 5 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <400> 2 Cys Gly Gly His Ala 1 5 <210> 3 <211> 5 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <400> 3 Cys Pro Gly His Ala 1 5 <210> 4 <211> 5 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <400> 4 Cys Gly Ala His Ala 1 5 <210> 5 <211> 5 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <400> 5 Cys Pro Ala His Ala 1 5 <210> 6 <211> 6 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <400> 6 Gly Cys Gly Gly His Ala 1 5 <210> 7 <211> 6 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <400> 7 Ala Cys Pro Gly His Ala 1 5 <210> 8 <211> 6 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <400> 8 Gly Cys Pro Gly His Ala 1 5 <210> 9 <211> 4 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <400> 9 Gly Gly Gly Gly 1 <210> 10 <211> 18 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <400> 10 Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr 1 5 10 15 Lys Gly <210> 11 <211> 19 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <400> 11 Gly Gly Ser Gly Gly Ser Lys Gly Ser Lys Gly Ser Lys Gly Ser Lys 1 5 10 15 Gly Ser Lys <210> 12 <211> twenty four <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <400> 12 Gly Gly Ser Gly Gly Ser Gly Lys Gly Gly Ser Gly Gly Ser Gly Lys 1 5 10 15 Gly Gly Ser Gly Gly Ser Gly Lys 20 <210> 13 <211> 483 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <400> 13 Glu Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Arg Val Thr Met Thr Cys Ser Ala Ser Ser Gly Val Asn Tyr Met 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Thr Ser Pro Arg Arg Trp Ile Tyr 35 40 45 Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Ser Met Glu Pro Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys His Gln Arg Gly Ser Tyr Thr Phe Gly 85 90 95 Gly Gly Thr Lys Leu Glu Ile Lys Arg Gly Ser Thr Ser Gly Ser Gly 100 105 110 Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln Val Gln Leu Val 115 120 125 Gln Pro Gly Ala Glu Val Val Lys Pro Gly Ala Ser Val Lys Leu Ser 130 135 140 Cys Lys Thr Ser Gly Tyr Thr Phe Thr Ser Asn Trp Met His Trp Val 145 150 155 160 Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Glu Ile Asp Pro 165 170 175 Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Asn Phe Gln Gly Lys Ala Lys 180 185 190 Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Val Ser Ser 195 200 205 Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Asn 210 215 220 Pro Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr 225 230 235 240 Val Ser Ser Gly Gly Gly Ala Ser Asp Lys Thr His Thr Cys Pro Pro 245 250 255 Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 260 265 270 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 275 280 285 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 290 295 300 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 305 310 315 320 Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 325 330 335 Leu His Gln Asp Trp Leu Asn Gly Lys Asp Tyr Lys Cys Lys Val Ser 340 345 350 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 355 360 365 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp 370 375 380 Glu Leu Thr Arg Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 385 390 395 400 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 405 410 415 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 420 425 430 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 435 440 445 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 450 455 460 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Ala Cys Pro 465 470 475 480 Gly His Ala <210> 14 <211> 483 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <400> 14 Gln Val Gln Leu Val Gln Pro Gly Ala Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Ser Asn 20 25 30 Trp Met His Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Asn Phe 50 55 60 Gln Gly Lys Ala Lys Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Val Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Ser Asn Pro Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Ser Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys 115 120 125 Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Ile Val Leu Thr Gln 130 135 140 Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Arg Val Thr Met Thr 145 150 155 160 Cys Ser Ala Ser Ser Gly Val Asn Tyr Met His Trp Tyr Gln Gln Lys 165 170 175 Pro Gly Thr Ser Pro Arg Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ala 180 185 190 Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr 195 200 205 Ser Leu Thr Ile Ser Ser Met Glu Pro Glu Asp Ala Ala Thr Tyr Tyr 210 215 220 Cys His Gln Arg Gly Ser Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu 225 230 235 240 Ile Lys Arg Gly Gly Gly Ala Ser Asp Lys Thr His Thr Cys Pro Pro 245 250 255 Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 260 265 270 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 275 280 285 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 290 295 300 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 305 310 315 320 Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 325 330 335 Leu His Gln Asp Trp Leu Asn Gly Lys Asp Tyr Lys Cys Lys Val Ser 340 345 350 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 355 360 365 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp 370 375 380 Glu Leu Thr Arg Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 385 390 395 400 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 405 410 415 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 420 425 430 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 435 440 445 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 450 455 460 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Ala Cys Pro 465 470 475 480 Gly His Ala <210> 15 <211> 483 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <400> 15 Glu Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Arg Val Thr Met Thr Cys Ser Ala Ser Ser Gly Val Asn Tyr Met 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Thr Ser Pro Arg Arg Trp Ile Tyr 35 40 45 Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Ser Met Glu Pro Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys His Gln Arg Gly Ser Tyr Thr Phe Gly 85 90 95 Gly Gly Thr Lys Leu Glu Ile Lys Arg Gly Ser Thr Ser Gly Ser Gly 100 105 110 Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln Val Gln Leu Val 115 120 125 Gln Pro Gly Ala Glu Val Val Lys Pro Gly Ala Ser Val Lys Leu Ser 130 135 140 Cys Lys Thr Ser Gly Tyr Thr Phe Thr Ser Asn Trp Met His Trp Val 145 150 155 160 Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Glu Ile Asp Pro 165 170 175 Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Asn Phe Gln Gly Lys Ala Lys 180 185 190 Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Val Ser Ser 195 200 205 Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Asn 210 215 220 Pro Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr 225 230 235 240 Val Ser Ser Gly Gly Gly Ala Ser Asp Lys Thr His Thr Cys Pro Pro 245 250 255 Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 260 265 270 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 275 280 285 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 290 295 300 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 305 310 315 320 Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 325 330 335 Leu His Gln Asp Trp Leu Asn Gly Lys Asp Tyr Lys Cys Lys Val Ser 340 345 350 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 355 360 365 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp 370 375 380 Glu Leu Thr Arg Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 385 390 395 400 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 405 410 415 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 420 425 430 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 435 440 445 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 450 455 460 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Cys Pro 465 470 475 480 Gly His Ala <210> 16 <211> 483 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <400> 16 Glu Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Arg Val Thr Met Thr Cys Ser Ala Ser Ser Gly Val Asn Tyr Met 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Thr Ser Pro Arg Arg Trp Ile Tyr 35 40 45 Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Ser Met Glu Pro Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys His Gln Arg Gly Ser Tyr Thr Phe Gly 85 90 95 Gly Gly Thr Lys Leu Glu Ile Lys Arg Gly Ser Thr Ser Gly Ser Gly 100 105 110 Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln Val Gln Leu Val 115 120 125 Gln Pro Gly Ala Glu Val Val Lys Pro Gly Ala Ser Val Lys Leu Ser 130 135 140 Cys Lys Thr Ser Gly Tyr Thr Phe Thr Ser Asn Trp Met His Trp Val 145 150 155 160 Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Glu Ile Asp Pro 165 170 175 Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Asn Phe Gln Gly Lys Ala Lys 180 185 190 Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Val Ser Ser 195 200 205 Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Asn 210 215 220 Pro Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr 225 230 235 240 Val Ser Ser Gly Gly Gly Ala Ser Asp Lys Thr His Thr Cys Pro Pro 245 250 255 Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 260 265 270 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 275 280 285 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 290 295 300 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 305 310 315 320 Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 325 330 335 Leu His Gln Asp Trp Leu Asn Gly Lys Asp Tyr Lys Cys Lys Val Ser 340 345 350 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 355 360 365 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp 370 375 380 Glu Leu Thr Arg Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 385 390 395 400 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 405 410 415 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 420 425 430 Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 435 440 445 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 450 455 460 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Cys Gly 465 470 475 480 Gly His Ala <210> 17 <211> 458 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <400> 17 Gln Val Gln Leu Val Gln Pro Gly Ala Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Ser Asn 20 25 30 Trp Met His Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Asn Phe 50 55 60 Gln Gly Lys Ala Lys Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Val Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Ser Asn Pro Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Ala Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Asp Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Arg Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Gly Gly Gly Ala Cys Pro Gly His Ala 450 455 <210> 18 <211> 458 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <400> 18 Gln Val Gln Leu Val Gln Pro Gly Ala Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Ser Asn 20 25 30 Trp Met His Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Asn Phe 50 55 60 Gln Gly Lys Ala Lys Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Val Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Ser Asn Pro Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Ala Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Asp Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Arg Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Gly Gly Gly Gly Cys Pro Gly His Ala 450 455 <210> 19 <211> 211 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <400> 19 Glu Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Arg Val Thr Met Thr Cys Ser Ala Ser Ser Gly Val Asn Tyr Met 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Thr Ser Pro Arg Arg Trp Ile Tyr 35 40 45 Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Ser Met Glu Pro Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys His Gln Arg Gly Ser Tyr Thr Phe Gly 85 90 95 Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val 100 105 110 Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser 115 120 125 Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln 130 135 140 Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val 145 150 155 160 Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu 165 170 175 Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu 180 185 190 Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg 195 200 205 Gly Glu Cys 210 <210> 20 <211> 489 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <400> 20 Glu Ile Val Leu Thr Gln Ser Pro Gly Ser Leu Ala Val Ser Pro Gly 1 5 10 15 Glu Arg Val Thr Met Ser Cys Lys Ser Ser Gln Ser Val Phe Phe Ser 20 25 30 Ser Ser Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Ile Pro Gly Gln 35 40 45 Ser Pro Arg Leu Leu Thr Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Ile Tyr Tyr Cys His Gln 85 90 95 Tyr Leu Ser Ser Arg Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 Arg Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser 115 120 125 Thr Lys Gly Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Val Val Lys 130 135 140 Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe 145 150 155 160 Thr Ser Tyr Tyr Ile His Trp Ile Lys Gln Thr Pro Gly Gln Gly Leu 165 170 175 Glu Trp Val Gly Val Ile Tyr Pro Gly Asn Asp Asp Ile Ser Tyr Asn 180 185 190 Gln Lys Phe Gln Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Thr 195 200 205 Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val 210 215 220 Tyr Tyr Cys Ala Arg Glu Val Arg Leu Arg Tyr Phe Asp Val Trp Gly 225 230 235 240 Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Ala Ser Asp Lys 245 250 255 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 260 265 270 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 275 280 285 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 290 295 300 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 305 310 315 320 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 325 330 335 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Asp 340 345 350 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 355 360 365 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 370 375 380 Leu Pro Pro Ser Arg Asp Glu Leu Thr Arg Asn Gln Val Ser Leu Thr 385 390 395 400 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 405 410 415 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 420 425 430 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 435 440 445 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 450 455 460 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 465 470 475 480 Gly Gly Gly Ala Cys Pro Gly His Ala 485 <210> 21 <211> 489 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <400> 21 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Ile Lys Gln Thr Pro Gly Gln Gly Leu Glu Trp Val 35 40 45 Gly Val Ile Tyr Pro Gly Asn Asp Asp Ile Ser Tyr Asn Gln Lys Phe 50 55 60 Gln Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Thr Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Val Arg Leu Arg Tyr Phe Asp Val Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly 115 120 125 Ser Gly Glu Gly Ser Thr Lys Gly Glu Ile Val Leu Thr Gln Ser Pro 130 135 140 Gly Ser Leu Ala Val Ser Pro Gly Glu Arg Val Thr Met Ser Cys Lys 145 150 155 160 Ser Ser Gln Ser Val Phe Phe Ser Ser Ser Gln Lys Asn Tyr Leu Ala 165 170 175 Trp Tyr Gln Gln Ile Pro Gly Gln Ser Pro Arg Leu Leu Thr Tyr Trp 180 185 190 Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly 195 200 205 Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro Glu Asp 210 215 220 Leu Ala Ile Tyr Tyr Cys His Gln Tyr Leu Ser Ser Arg Thr Phe Gly 225 230 235 240 Gln Gly Thr Lys Leu Glu Ile Lys Arg Gly Gly Gly Ala Ser Asp Lys 245 250 255 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 260 265 270 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 275 280 285 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 290 295 300 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 305 310 315 320 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 325 330 335 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Asp 340 345 350 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 355 360 365 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 370 375 380 Leu Pro Pro Ser Arg Asp Glu Leu Thr Arg Asn Gln Val Ser Leu Thr 385 390 395 400 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 405 410 415 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 420 425 430 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 435 440 445 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 450 455 460 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 465 470 475 480 Gly Gly Gly Ala Cys Pro Gly His Ala 485 <210> 22 <211> 489 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <400> 22 Glu Ile Val Leu Thr Gln Ser Pro Gly Ser Leu Ala Val Ser Pro Gly 1 5 10 15 Glu Arg Val Thr Met Ser Cys Lys Ser Ser Gln Ser Val Phe Phe Ser 20 25 30 Ser Ser Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Ile Pro Gly Gln 35 40 45 Ser Pro Arg Leu Leu Thr Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Ile Tyr Tyr Cys His Gln 85 90 95 Tyr Leu Ser Ser Arg Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 110 Arg Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser 115 120 125 Thr Lys Gly Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Val Val Lys 130 135 140 Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe 145 150 155 160 Thr Ser Tyr Tyr Ile His Trp Ile Lys Gln Thr Pro Gly Gln Gly Leu 165 170 175 Glu Trp Val Gly Val Ile Tyr Pro Gly Asn Asp Asp Ile Ser Tyr Asn 180 185 190 Gln Lys Phe Gln Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Thr 195 200 205 Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val 210 215 220 Tyr Tyr Cys Ala Arg Glu Val Arg Leu Arg Tyr Phe Asp Val Trp Gly 225 230 235 240 Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Ala Ser Asp Lys 245 250 255 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 260 265 270 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 275 280 285 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 290 295 300 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 305 310 315 320 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 325 330 335 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Asp 340 345 350 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 355 360 365 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 370 375 380 Leu Pro Pro Ser Arg Asp Glu Leu Thr Arg Asn Gln Val Ser Leu Thr 385 390 395 400 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 405 410 415 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 420 425 430 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 435 440 445 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 450 455 460 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 465 470 475 480 Gly Gly Gly Gly Cys Pro Gly His Ala 485 <210> 23 <211> 489 <212> PRT <213> Artificial Sequence <220> <223> Synthetic sequence <400> 23 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Ile His Trp Ile Lys Gln Thr Pro Gly Gln Gly Leu Glu Trp Val 35 40 45 Gly Val Ile Tyr Pro Gly Asn Asp Asp Ile Ser Tyr Asn Gln Lys Phe 50 55 60 Gln Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Thr Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Val Arg Leu Arg Tyr Phe Asp Val Trp Gly Gln Gly Thr 100 105 110 Thr Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly 115 120 125 Ser Gly Glu Gly Ser Thr Lys Gly Glu Ile Val Leu Thr Gln Ser Pro 130 135 140 Gly Ser Leu Ala Val Ser Pro Gly Glu Arg Val Thr Met Ser Cys Lys 145 150 155 160 Ser Ser Gln Ser Val Phe Phe Ser Ser Ser Gln Lys Asn Tyr Leu Ala 165 170 175 Trp Tyr Gln Gln Ile Pro Gly Gln Ser Pro Arg Leu Leu Thr Tyr Trp 180 185 190 Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly 195 200 205 Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro Glu Asp 210 215 220 Leu Ala Ile Tyr Tyr Cys His Gln Tyr Leu Ser Ser Arg Thr Phe Gly 225 230 235 240 Gln Gly Thr Lys Leu Glu Ile Lys Arg Gly Gly Gly Ala Ser Asp Lys 245 250 255 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 260 265 270 Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 275 280 285 Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 290 295 300 Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 305 310 315 320 Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 325 330 335 Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Asp 340 345 350 Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 355 360 365 Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 370 375 380 Leu Pro Pro Ser Arg Asp Glu Leu Thr Arg Asn Gln Val Ser Leu Thr 385 390 395 400 Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 405 410 415 Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 420 425 430 Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 435 440 445 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 450 455 460 Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 465 470 475 480 Gly Gly Gly Gly Cys Pro Gly His Ala 485 <210> 24 <211> 487 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <400> 24 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Pro Leu Ile Tyr 35 40 45 Ala Pro Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu 65 70 75 80 Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Phe Asn Pro Pro Thr 85 90 95 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Gly Ser Thr Ser Gly 100 105 110 Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Val Gln 115 120 125 Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg 130 135 140 Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asn Met His 145 150 155 160 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Ala Ile 165 170 175 Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg 180 185 190 Phe Thr Ile Ser Val Asp Lys Ser Lys Asn Thr Leu Tyr Leu Gln Met 195 200 205 Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val 210 215 220 Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp Gly Gln Gly 225 230 235 240 Thr Leu Val Thr Val Ser Ser Gly Gly Gly Ala Ser Asp Lys Thr His 245 250 255 Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 260 265 270 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 275 280 285 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 290 295 300 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 305 310 315 320 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 325 330 335 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Asp Tyr Lys 340 345 350 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 355 360 365 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 370 375 380 Pro Ser Arg Asp Glu Leu Thr Arg Asn Gln Val Ser Leu Thr Cys Leu 385 390 395 400 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 405 410 415 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 420 425 430 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 435 440 445 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 450 455 460 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly 465 470 475 480 Gly Ala Cys Pro Gly His Ala 485 <210> 25 <211> 487 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <400> 25 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Asn Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Arg Phe Thr Ile Ser Val Asp Lys Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser 115 120 125 Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Asp Ile Gln Met 130 135 140 Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr 145 150 155 160 Ile Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr Gln 165 170 175 Gln Lys Pro Gly Lys Ala Pro Lys Pro Leu Ile Tyr Ala Pro Ser Asn 180 185 190 Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr 195 200 205 Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr 210 215 220 Tyr Tyr Cys Gln Gln Trp Ser Phe Asn Pro Pro Thr Phe Gly Gln Gly 225 230 235 240 Thr Lys Val Glu Ile Lys Arg Gly Gly Gly Ala Ser Asp Lys Thr His 245 250 255 Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 260 265 270 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 275 280 285 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 290 295 300 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 305 310 315 320 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 325 330 335 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Asp Tyr Lys 340 345 350 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 355 360 365 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 370 375 380 Pro Ser Arg Asp Glu Leu Thr Arg Asn Gln Val Ser Leu Thr Cys Leu 385 390 395 400 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 405 410 415 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 420 425 430 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 435 440 445 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 450 455 460 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly 465 470 475 480 Gly Ala Cys Pro Gly His Ala 485 <210> 26 <211> 487 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <400> 26 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Asn Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Arg Phe Thr Ile Ser Val Asp Lys Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser 115 120 125 Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Asp Ile Gln Met 130 135 140 Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr 145 150 155 160 Ile Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr Gln 165 170 175 Gln Lys Pro Gly Lys Ala Pro Lys Pro Leu Ile Tyr Ala Pro Ser Asn 180 185 190 Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr 195 200 205 Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr 210 215 220 Tyr Tyr Cys Gln Gln Trp Ser Phe Asn Pro Pro Thr Phe Gly Gln Gly 225 230 235 240 Thr Lys Val Glu Ile Lys Arg Gly Gly Gly Ala Ser Asp Lys Thr His 245 250 255 Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 260 265 270 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 275 280 285 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 290 295 300 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 305 310 315 320 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 325 330 335 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Asp Tyr Lys 340 345 350 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 355 360 365 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 370 375 380 Pro Ser Arg Asp Glu Leu Thr Arg Asn Gln Val Ser Leu Thr Cys Leu 385 390 395 400 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 405 410 415 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 420 425 430 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 435 440 445 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 450 455 460 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly 465 470 475 480 Gly Gly Cys Pro Gly His Ala 485 <210> 27 <211> 487 <212> PRT <213> Artificial Sequence <220> <223> Synthetic sequence <400> 27 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Pro Leu Ile Tyr 35 40 45 Ala Pro Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu 65 70 75 80 Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Phe Asn Pro Pro Thr 85 90 95 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Gly Ser Thr Ser Gly 100 105 110 Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Val Gln 115 120 125 Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg 130 135 140 Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asn Met His 145 150 155 160 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Ala Ile 165 170 175 Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg 180 185 190 Phe Thr Ile Ser Val Asp Lys Ser Lys Asn Thr Leu Tyr Leu Gln Met 195 200 205 Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val 210 215 220 Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp Gly Gln Gly 225 230 235 240 Thr Leu Val Thr Val Ser Ser Gly Gly Gly Ala Ser Asp Lys Thr His 245 250 255 Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 260 265 270 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 275 280 285 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 290 295 300 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 305 310 315 320 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 325 330 335 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Asp Tyr Lys 340 345 350 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 355 360 365 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 370 375 380 Pro Ser Arg Asp Glu Leu Thr Arg Asn Gln Val Ser Leu Thr Cys Leu 385 390 395 400 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 405 410 415 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 420 425 430 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 435 440 445 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 450 455 460 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly 465 470 475 480 Gly Gly Cys Gly Gly His Ala 485 <210> 28 <211> 487 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <400> 28 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Asn Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Arg Phe Thr Ile Ser Val Asp Lys Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser 115 120 125 Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Asp Ile Gln Met 130 135 140 Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr 145 150 155 160 Ile Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr Gln 165 170 175 Gln Lys Pro Gly Lys Ala Pro Lys Pro Leu Ile Tyr Ala Pro Ser Asn 180 185 190 Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr 195 200 205 Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr 210 215 220 Tyr Tyr Cys Gln Gln Trp Ser Phe Asn Pro Pro Thr Phe Gly Gln Gly 225 230 235 240 Thr Lys Val Glu Ile Lys Arg Gly Gly Gly Ala Ser Asp Lys Thr His 245 250 255 Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 260 265 270 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 275 280 285 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 290 295 300 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 305 310 315 320 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 325 330 335 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Asp Tyr Lys 340 345 350 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 355 360 365 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 370 375 380 Pro Ser Arg Asp Glu Leu Thr Arg Asn Gln Val Ser Leu Thr Cys Leu 385 390 395 400 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 405 410 415 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 420 425 430 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 435 440 445 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 450 455 460 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly 465 470 475 480 Gly Gly Cys Gly Gly His Ala 485 <210> 29 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <400> 29 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 1 5 10 15 Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 20 25 30 Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 35 40 45 Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr 65 70 75 80 Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Arg 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105 <210> 30 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <400> 30 Glu Val Lys Leu Gln Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala 20 25 30 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Glu Ile Gly Asn Lys Gly Asn Asn His Ala Thr Tyr Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asp Ser Lys Ser Arg 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Gly Thr Tyr 85 90 95 Tyr Cys Thr Thr Arg Phe Ala Tyr Trp Gly Gln Gly Thr Thr Val Thr 100 105 110 Val Ser Ser 115 <210> 31 <211> 481 <212> PRT <213> artificial sequence <220> <223> synthetic sequence <400> 31 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 1 5 10 15 Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 20 25 30 Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 35 40 45 Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr 65 70 75 80 Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Arg 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Gly Ser Thr Ser 100 105 110 Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Val 115 120 125 Lys Leu Gln Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met 130 135 140 Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met 145 150 155 160 Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu 165 170 175 Ile Gly Asn Lys Gly Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val 180 185 190 Lys Gly Arg Phe Thr Val Ser Arg Asp Asp Ser Lys Ser Arg Val Tyr 195 200 205 Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Gly Thr Tyr Tyr Cys 210 215 220 Thr Thr Arg Phe Ala Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser 225 230 235 240 Ser Gly Gly Gly Ala Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro 245 250 255 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 260 265 270 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 275 280 285 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 290 295 300 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 305 310 315 320 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 325 330 335 Gln Asp Trp Leu Asn Gly Lys Asp Tyr Lys Cys Lys Val Ser Asn Lys 340 345 350 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 355 360 365 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 370 375 380 Thr Arg Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 385 390 395 400 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 405 410 415 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 420 425 430 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 435 440 445 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 450 455 460 Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Ala Cys Pro Gly His 465 470 475 480 Ala <210> 32 <211> 481 <212> PRT <213> artificial sequence <220> <223> synthetic sequence <400> 32 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 1 5 10 15 Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 20 25 30 Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 35 40 45 Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr 65 70 75 80 Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Phe Pro Arg 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Gly Ser Thr Ser 100 105 110 Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Val 115 120 125 Lys Leu Gln Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met 130 135 140 Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met 145 150 155 160 Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu 165 170 175 Ile Gly Asn Lys Gly Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val 180 185 190 Lys Gly Arg Phe Thr Val Ser Arg Asp Asp Ser Lys Ser Arg Val Tyr 195 200 205 Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Gly Thr Tyr Tyr Cys 210 215 220 Thr Thr Arg Phe Ala Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser 225 230 235 240 Ser Gly Gly Gly Ala Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro 245 250 255 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 260 265 270 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 275 280 285 Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 290 295 300 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 305 310 315 320 Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 325 330 335 Gln Asp Trp Leu Asn Gly Lys Asp Tyr Lys Cys Lys Val Ser Asn Lys 340 345 350 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 355 360 365 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu 370 375 380 Thr Arg Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 385 390 395 400 Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn 405 410 415 Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 420 425 430 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 435 440 445 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 450 455 460 Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Cys Gly Gly His 465 470 475 480 Ala <210> 33 <211> 487 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <400> 33 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Ser Thr Ser Gly 100 105 110 Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Val Gln 115 120 125 Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg 130 135 140 Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Asn Ser Phe Ala Met Ser 145 150 155 160 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile 165 170 175 Ser Gly Ser Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg 180 185 190 Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met 195 200 205 Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys Ala Lys Asp 210 215 220 Lys Ile Leu Trp Phe Gly Glu Pro Val Phe Asp Tyr Trp Gly Gln Gly 225 230 235 240 Thr Leu Val Thr Val Ser Ser Gly Gly Gly Ala Ser Asp Lys Thr His 245 250 255 Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 260 265 270 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 275 280 285 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 290 295 300 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 305 310 315 320 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 325 330 335 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Asp Tyr Lys 340 345 350 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 355 360 365 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 370 375 380 Pro Ser Arg Asp Glu Leu Thr Arg Asn Gln Val Ser Leu Thr Cys Leu 385 390 395 400 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 405 410 415 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 420 425 430 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 435 440 445 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 450 455 460 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly 465 470 475 480 Gly Ala Cys Pro Gly His Ala 485 <210> 34 <211> 487 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <400> 34 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Asn Ser Phe 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Gly Ser Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Lys Asp Lys Ile Leu Trp Phe Gly Glu Pro Val Phe Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser 115 120 125 Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Ile Val Leu 130 135 140 Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr 145 150 155 160 Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr 165 170 175 Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser 180 185 190 Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 195 200 205 Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala 210 215 220 Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Thr Phe Gly Gln 225 230 235 240 Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Ala Ser Asp Lys Thr His 245 250 255 Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 260 265 270 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 275 280 285 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 290 295 300 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 305 310 315 320 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 325 330 335 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Asp Tyr Lys 340 345 350 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 355 360 365 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 370 375 380 Pro Ser Arg Asp Glu Leu Thr Arg Asn Gln Val Ser Leu Thr Cys Leu 385 390 395 400 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 405 410 415 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 420 425 430 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 435 440 445 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 450 455 460 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly 465 470 475 480 Gly Ala Cys Pro Gly His Ala 485 <210> 35 <211> 487 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 35 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Gly Ser Thr Ser Gly 100 105 110 Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Val Gln 115 120 125 Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg 130 135 140 Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Asn Ser Phe Ala Met Ser 145 150 155 160 Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile 165 170 175 Ser Gly Ser Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg 180 185 190 Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met 195 200 205 Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys Ala Lys Asp 210 215 220 Lys Ile Leu Trp Phe Gly Glu Pro Val Phe Asp Tyr Trp Gly Gln Gly 225 230 235 240 Thr Leu Val Thr Val Ser Ser Gly Gly Gly Ala Ser Asp Lys Thr His 245 250 255 Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 260 265 270 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 275 280 285 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 290 295 300 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 305 310 315 320 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 325 330 335 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Asp Tyr Lys 340 345 350 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 355 360 365 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 370 375 380 Pro Ser Arg Asp Glu Leu Thr Arg Asn Gln Val Ser Leu Thr Cys Leu 385 390 395 400 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 405 410 415 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 420 425 430 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 435 440 445 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 450 455 460 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly 465 470 475 480 Gly Gly Cys Pro Gly His Ala 485 <210> 36 <211> 487 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <400> 36 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Asn Ser Phe 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Gly Ser Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Lys Asp Lys Ile Leu Trp Phe Gly Glu Pro Val Phe Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser 115 120 125 Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Ile Val Leu 130 135 140 Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr 145 150 155 160 Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr 165 170 175 Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser 180 185 190 Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 195 200 205 Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala 210 215 220 Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Thr Phe Gly Gln 225 230 235 240 Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Ala Ser Asp Lys Thr His 245 250 255 Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 260 265 270 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 275 280 285 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 290 295 300 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 305 310 315 320 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 325 330 335 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Asp Tyr Lys 340 345 350 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 355 360 365 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 370 375 380 Pro Ser Arg Asp Glu Leu Thr Arg Asn Gln Val Ser Leu Thr Cys Leu 385 390 395 400 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 405 410 415 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 420 425 430 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 435 440 445 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 450 455 460 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly 465 470 475 480 Gly Gly Cys Pro Gly His Ala 485 <210> 37 <211> 47 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Sequence <220> <221> Variant <222> 2 <223> Xaa is 2-isobutylalanine <400> 37 His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 1 5 10 15 Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly Gly 20 25 30 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Cys 35 40 45 <210> 38 <211> 14 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <220> <221> Variants <222> 7 <223> D-form <220> <221> Variants <222> 10 <223> D-form <400> 38 Cys Ser Gly Gly Gly Gly Phe Cys Phe Trp Lys Thr Cys Thr 1 5 10 <210> 39 <211> 46 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <400> 39 Cys Ser Asn Leu Ser Thr Cys Val Leu Gly Lys Leu Ser Gln Glu Leu 1 5 10 15 His Lys Leu Gln Thr Tyr Pro Arg Thr Asn Thr Gly Ser Gly Thr Pro 20 25 30 Gly Gly Gly Ser Gly Gly Gly Ser Ala Cys Pro Gly His Ala 35 40 45 <210> 40 <211> 55 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <400> 40 Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn 1 5 10 15 Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His 20 25 30 Asn Phe Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 35 40 45 Ser Ala Cys Pro Gly His Ala 50 55 <210> 41 <211> twenty three <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <220> <221> Variants <222> 1 <223> Xaa is pyroglutamic acid <220> <221> Variants <222> 6 <223> D-form <400> 41 Xaa His Trp Ser Trp Leu Leu Arg Pro Gly Gly Ser Gly Ser Gly Gly 1 5 10 15 Ser Gly Cys Gly Gly His Ala 20 <210> 42 <211> 18 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <400> 42 Glu Gly Glu Gly Glu Ala Gly Gly Lys Gly Ala Gly Lys Gly Ala Gly 1 5 10 15 Lys Gly <210> 43 <211> 18 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <400> 43 Glu Asp Glu Asp Glu Ala Gly Gly Lys Gly Ala Gly Lys Gly Ala Gly 1 5 10 15 Lys Gly <210> 44 <211> 9 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <220> <221> Variants <222> 6,8 <223> Xaa is a PEGylated amino acid with four EG units <400> 44 Glu Gly Glu Gly Glu Xaa Lys Xaa Lys 1 5 <210> 45 <211> 12 <212> PRT <213> Artificial sequence <220> <223> synthetic sequence <400> 45 Lys Gly Ala Gly Gly Lys Gly Ala Gly Gly Lys Gly 1 5 10 <210> 46 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 46 Glu Gly Glu Gly Glu Ala Gly Lys Gly Ala Gly 1 5 10 <210> 47 <211> 144 <212> PRT <213> Artificial sequence <220> <223> Synthetic sequence <400> 47 Ala Cys Pro Gly His Ala Gly Gly Gly Gly Ser Ala Pro Thr Ser Ser 1 5 10 15 Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His Leu Leu Leu Asp Leu 20 25 30 Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr 35 40 45 Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu 50 55 60 Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys Pro Leu Glu Glu Val 65 70 75 80 Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg Pro Arg Asp Leu 85 90 95 Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr 100 105 110 Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe 115 120 125 Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile Ile Ser Thr Leu Thr 130 135 140

Claims

1. A composite polypeptide comprising a parent polypeptide and a metal binding domain, wherein the amino acid sequence of the metal binding domain is as shown in SEQ ID NO: 6-8, and the metal binding domain is located at the N- or C-terminus of the parent polypeptide.

2. The composite polypeptide as claimed in claim 1, wherein the parent polypeptide is a peptide hormone, a receptor binding peptidomimetic ligand, an antibody fragment or a cytokine.

3. A molecular construct comprising a composite polypeptide as claimed in claim 1 and a functional component, wherein the functional component has a sulfhydryl (SH)-reactive group that can be coupled to the thiol group of the cysteine ​​residue in the metal binding domain.

4. The molecular construct of claim 3, wherein the SH-reactive group is a maleimide group, an iodoacetyl group, a bromoacetyl group, a vinylsulfone group, a monosulfone group, a methylsulfonylbenzothiazolyl group or a 2-pyridyldithiol group.

5. The molecular construct of claim 3, wherein the composite polypeptide is in the form of a dimer, each with a functional component coupled thereto.

6. The molecular construct of claim 3, wherein the functional component comprises: (i) a central core, wherein the central core comprises: 2 to 10 lysine (K) residues, Optionally, one or more fillers, wherein any two of said K residues are adjacent to each other or separated by the filler, Optionally, a terminal spacer, wherein the terminal spacer is an N-terminal spacer connected to the N-terminus of the first K residue or a C-terminal spacer connected to the C-terminus of the last K residue, and the filler and the terminal spacer independently comprise at least: (1) 1 to 12 non-K amino acid residues, or (2) a PEGylated amino acid having 2 to 12 ethylene glycol (EG) repeating units, and The SH-reactive group is linked to the central core by forming an amide bond with the first or last K residue, or when the terminal spacer is present, the SH-reactive group is linked to the central core by forming an amide bond with the terminal amino acid residue of the terminal spacer; and (ii) 2 to 10 target components, effector components or pharmacokinetic components, wherein: Each targeting component, effector component or pharmacokinetic component is linked to the K residue of the central core, or When the molecular construct further comprises 2 to 10 connecting arms, one end of each connecting arm is connected to the K residue of the central core by forming an amide bond with the ε-amino group of the K residue of the central core, and the other end of each connecting arm is connected to each target component, effector component or pharmacokinetic component, wherein the connecting arm is a polypeptide comprising 2-12 non-K amino acid residues; or a pegylated amino acid chain having 2 to 24 EG repeating units.

7. The molecular construct of claim 6, wherein the central core carries a local negative charge at or near the amino acid residue to which the SH-reactive group is attached.

8. The molecular construct of claim 7, wherein the central core has at least one glutamic acid (E) residue or aspartic acid (D) residue at or adjacent to the amino acid residue to which the SH-reactive group is attached.

9. The molecular construct of claim 7, wherein the local negative charge appears at the first 5 to 15 amino acid residues from the amino acid residue to which the SH-reactive group is attached.

10. The molecular construct of claim 7, wherein the effector element is a negatively charged chemical entity.

11. The molecular construct of claim 7, wherein the pharmacokinetic component is a C8-28 fatty acid derivative or a C8-28 dibasic fatty acid derivative, wherein the ε-amino group of the K residue is linked to the C8-28 fatty acid derivative or the C8-28 dibasic fatty acid derivative.